oritavancin profile

oritavancin : A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	16136912
CHEBI ID	82699
SCHEMBL ID	9947049
MeSH ID	M0438261

Synonym
ly-333328
171099-57-3
oritavancin
ly333328
chlorobiphenyl-chloroeremomycin
(4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabinohexopyranosyl)-n3''-(p-(p-chlorophenyl)benzyl)vancomycin
ly 333328
unii-pug62frz2e
pug62frz2e ,
oritavancin [inn]
(4'r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3)' -(p-(p-chlorophenyl)benzyl)vancomycin
chebi:82699 ,
DB04911
VHFGEBVPHAGQPI-LXKZPTCJSA-N
oritavancin [mart.]
(4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n(sup 3)''-(p-(p-chlorophenyl)benzyl)vancomycin
vancomycin, 22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n3''-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)-, (4''r)-
oritavancin [mi]
oritavancin [who-dd]
oritavancin [vandf]
(4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin
SCHEMBL9947049
NCGC00485478-01
AKOS032944863
oritavancin(ly-333328)
DTXSID20897570 ,
oritavancin; ly-333328
EX-A2372
Q7102878
gtpl10877
orita-vancin
bdbm513037
NCGC00485478-02
oritavancinum
oritavancine
dtxcid701326917
vancomycin, 22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n3''-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)-, (4''r)-
(4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3)''-(p-(p-chlorophenyl)benzyl)vancomycin
j01xa05
oritavancin (mart.)
oritavancina

Research Excerpts

Overview

Oritavancin is a lipoglycopeptide with activity against gram-positive pathogens including vancomycin-resistant enterococci. It is an outpatient treatment alternative for cellulitis patients whose only justification for admission is the presence of one or more risk factors for treatment failure.

Excerpt	Reference	Relevance
"Oritavancin is a lipoglycopeptide with multiple mechanisms of action that contribute to its bactericidal action against exponentially growing gram-positive pathogens, including the inhibition of cell wall synthesis and perturbation of membrane barrier function."	( Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Arhin, FF; Belley, A; Beveridge, T; Harris, R; McKay, G; Moeck, G; Neesham-Grenon, E; Parr, TR, 2009)	2.52
"Oritavancin is a lipoglycopeptide with activity against gram-positive pathogens including vancomycin-resistant enterococci. "	( Impact of human serum albumin on oritavancin in vitro activity against enterococci. Arhin, FF; Beaulieu, S; McKay, GA; Moeck, G; Parr, TR; Sarmiento, I, 2009)	2.08
"Oritavancin is an investigational lipoglycopeptide in clinical development for the treatment of acute bacterial skin and skin structure infections. "	( Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Arhin, FF; Beaulieu, S; Belley, A; Fadhil, I; McKay, GA; Moeck, G; Parr, TR; Sarmiento, I, 2010)	3.25
"Oritavancin is a new-generation semisynthetic lipoglycopeptide antibiotic used to prevent the spread of vancomycin-resistant Gram-positive bacteria. "	( Strategy for Producing the High-Quality Glycopeptide Antibiotic A82846B in Chen, XA; Ge, M; Li, YQ; Mo, XT; Qian, H; Wei, W; Zhao, QW, 2021)	2.06
"Oritavancin is a novel, broad-spectrum antibiotic which provides an entire treatment course for cellulitis with one dose."	( Finding the niche: An interprofessional approach to defining oritavancin use criteria in the emergency department. Baxa, J; McCreary, E; Pulia, M; Schulz, L, 2020)	1.52
"Oritavancin is an outpatient treatment alternative for cellulitis patients whose only justification for planned admission is the presence of one or more risk factors for treatment failure."	( Finding the niche: An interprofessional approach to defining oritavancin use criteria in the emergency department. Baxa, J; McCreary, E; Pulia, M; Schulz, L, 2020)	2.24
"Oritavancin is a novel antibiotic approved for the treatment of skin and soft tissue infections that is administered as a one-time infusion."	( Effectiveness of oritavancin for management of skin and soft tissue infections in the emergency department: A case series. Dretske, D; Pulia, M; Schulz, L; Sharp, B; Werner, E, 2021)	1.68
"Oritavancin is a lipoglycopeptide antibiotic with in vitro bactericidal activity against gram-positive pathogens indicated for use in adults with acute bacterial skin and skin structure infections (ABSSSI). "	( Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital. Castro-Lainez, M; Kosler, S; Lowery, E; Patel, P; Saddler, K; Sierra-Hoffman, M; Stevens, ML; Sul, J; Zhang, J, 2021)	2.32
"Oritavancin is a lipoglycopeptide antibiotic that exhibits potent activities against vancomycin-resistant Gram-positive pathogens. "	( Inhibition of Staphylococcus aureus Cell Wall Biosynthesis by Desleucyl-Oritavancin: a Quantitative Peptidoglycan Composition Analysis by Mass Spectrometry. Chang, JD; Foster, EE; Kim, SJ; Ramirez, AJ; Thadani, AN, 2017)	2.13
"Oritavancin is a novel long-acting lipoglycopeptide approved by the U.S."	( Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin. Darmelio, M; Delaportas, DJ; Estrada, SJ, 2017)	1.4
"Oritavancin is a lipoglycopeptide antibiotic approved for use in acute bacterial skin and skin structure infections as a single 1200-mg parenteral dose. "	( Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections. Dela-Pena, J; Dworkin, E; Rose, WE; Schulz, LT, 2018)	2.28
"Oritavancin is a lipoglycopeptide with bactericidal activity against Gram-positive organisms. "	( Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies. Corey, GR; Dudley, MN; Loutit, J; Moeck, G; O'Riordan, W; Wikler, M, 2018)	2.22
"Oritavancin is a long-acting, semisynthetic lipoglycopeptide antibiotic with rapid concentration-dependent bactericidal activity against many Gram-positive organisms."	( Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review. Chastain, DB; Davis, A, 2019)	1.49
"Oritavancin is a novel lipoglycopeptide agent with in vitro activity against enterococci, including vancomycin-resistant VanA-type Enterococcus faecium."	( In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci. Danziger, LH; Harrington, AT; Meyer, K; Wenzler, E; Wu, T, 2019)	1.55
"Oritavancin is a long half-life lipoglycopeptide with broad activity against Gram-positive bacteria."	( Oritavancin polymethylmethacrylate (PMMA)-compressive strength testing and in vitro elution. Berglund, LJ; Greenwood-Quaintance, KE; Mandrekar, J; Patel, R; Schmidt-Malan, SM, 2019)	2.68
"Oritavancin appears to be a promising antimicrobial alternative to vancomycin (with additional activity against Staphylococcus and Enterococcus resistant to vancomycin) for the treatment of complicated Gram-positive skin and skin-structure infections."	( Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens. Das, B; Sarkar, C; Schachter, J, 2013)	2.55
"Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria. "	( Single-dose oritavancin in the treatment of acute bacterial skin infections. Corey, GR; Giordano, P; Good, S; Gupta, S; Jiang, H; Kabler, H; Lucasti, C; Mehra, P; Moeck, G; O'Riordan, W; Overcash, JS; Perez, A; Porwal, A, 2014)	2.22
"Oritavancin (Orbactiv(®)) is a lipoglycopeptide antibacterial drug with activity against Gram-positive bacteria developed by The Medicines Company as a single-dose treatment for acute bacterial skin and skin structure infections (ABSSSI). "	( Oritavancin: first global approval. Markham, A, 2014)	3.29
"Oritavancin is a lipoglycopeptide antibiotic with rapid bactericidal activity against gram-positive bacteria. "	( Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Bubnova, N; Corey, GR; Good, S; Green, S; Heller, B; Jiang, H; Keech, R; Manos, P; Moeck, G; O'Riordan, W; Singh, R; Wikler, M, 2015)	2.24
"Oritavancin is a semisynthetic derivative of the glycopeptide antibiotic chloroeremomycin with activity against Gram-positive pathogens, including vancomycin-resistant staphylococci and enterococci. "	( Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin. Bendas, G; Bierbaum, G; Engels, I; Falkenstein-Paul, H; Grein, F; Müller, A; Münch, D; Reder-Christ, K; Sahl, HG; Schneider, T, 2015)	2.06
"Oritavancin is a recently approved lipoglycopeptide antimicrobial agent with activity against Gram-positive pathogens. "	( Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. Arhin, FF; Jones, RN; Mendes, RE; Moeck, G; Turnidge, JD, 2015)	2.09
"Oritavancin is a concentration-dependent, rapid bactericidal agent approved for the treatment of ABSSSIs."	( Oritavancin for acute bacterial skin and skin structure infections. Corey, GR; Fowler, VG; Messina, JA, 2015)	2.58
"Oritavancin is a concentration-dependent, rapid bactericidal agent approved for the treatment of ABSSSIs."	( Oritavancin for acute bacterial skin and skin structure infections. Corey, GR; Fowler, VG; Messina, JA, 2015)	2.58
"If oritavancin is proven to be a cost-effective strategy for outpatient treatment and prevents complications of prolonged i.v. "	( Oritavancin for acute bacterial skin and skin structure infections. Corey, GR; Fowler, VG; Messina, JA, 2015)	2.48
"Oritavancin is a lipoglycopeptide antibiotic with activity against Gram-positive bacteria. "	( Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Ambrose, PG; Bellibas, SE; Bhavnani, SM; Moeck, G; Rubino, CM, 2015)	2.09
"Oritavancin is a lipoglycopeptide antibiotic that has been shown to be effective for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). "	( Oritavancin: A Long-Half-Life Lipoglycopeptide. Saravolatz, LD; Stein, GE, 2015)	3.3
"Oritavancin (Orbactiv(®)) is a new generation lipoglycopeptide approved for use in adult patients with acute bacterial skin and skin structure infections (ABSSSI). "	( Oritavancin: a review in acute bacterial skin and skin structure infections. Scott, LJ; Syed, YY, 2015)	3.3
"Oritavancin is a lipoglycopeptide that has been approved for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) caused by susceptible organisms. "	( In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014. Arhin, FF; Biedenbach, DJ; Lynch, TF; Moeck, G; Sahm, DF, 2015)	2.18
"Oritavancin is a lipoglycopeptide antibiotic that has a mechanism of action and broad-spectrum gram-positive coverage similar to other glycopeptides. "	( Oritavancin: A Novel Lipoglycopeptide. Belliveau, P; Durand, C; Mattox, J, 2016)	3.32
"Oritavancin is a new lipoglycopeptide antibacterial agent with an exceptionally long terminal half-life and a rapid bactericidal effect. "	( Oritavancin: a long-acting antibacterial lipoglycopeptide. Kaasch, AJ; Seifert, H, 2016)	3.32
"Oritavancin is a lipoglycopeptide antibiotic with bactericidal activity against gram-positive bacteria, including MRSA."	( Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis. Cyr, PL; Dufour, S; Fan, W; Jensen, IS; Lodise, TP; Nicolau, DP; Sulham, KA; Wu, E, 2016)	1.61
"Oritavancin is a lipoglycopeptide with activity against Gram-positive bacteria, including drug-resistant pathogens."	( In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. Baines, SD; Freeman, J; O'Connor, R; Wilcox, MH, 2008)	1.29
"Oritavancin is a semisynthetic lipoglycopeptide in clinical development for serious gram-positive infections. "	( Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Arhin, FF; Belley, A; McKay, GA; Moeck, G; Neesham-Grenon, E; Parr, TR, 2008)	2.03
"Oritavancin (LY-333328) is a semisynthetic lipoglycopeptide for the treatment of serious infections with Gram-positive pathogens, especially methicillin-resistant Staphylococcus aureus and complicated skin and soft tissue infections. "	( Oritavancin for skin infections. Anderson, DL, 2008)	3.23
"Oritavancin is a amphiphilic derivative of vancomycin showing fast and extensive killing activities against multi-resistant (including vancomycin insusceptible) Gram-positive organisms with no marked toxicity towards eukaryotic cells."	( Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization. Domenech, O; Dufrêne, Y; Francius, G; Mingeot-Leclercq, MP; Tulkens, PM; Van Bambeke, F, 2009)	1.42
"Oritavancin is a promising new alternative in clinical development that has potent antimicrobial activity against both staphylococcal and enterococcal vancomycin-resistant pathogens."	( Vancomycin and oritavancin have different modes of action in Enterococcus faecium. Dietrich, E; Far, AR; Kim, SJ; Parr, TR; Patti, GJ; Schaefer, J; Tanaka, KS; Yu, TY, 2009)	1.43
"Oritavancin is a novel glycopeptide antimicrobial agent with potent in vitro activity against a wide variety of gram-positive bacteria, including multidrug-resistant strains of staphylococci and enterococci. "	( Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Ambrose, PG; Bhavnani, SM; Forrest, A; McCollam, JS; Rubino, CM; Van Wart, SA, 2009)	3.24
"Oritavancin is a lipoglycopeptide with broad activity against gram-positive bacteria. "	( Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study. Darpo, B; Lee, SK; Mason, JW; Moon, TE; Sills, N, 2010)	3.25
"Oritavancin is a lipoglycopeptide antibiotic under investigation for the treatment of serious infections caused by Gram-positive bacteria. "	( Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains. Bouza, E; Burillo, A, 2010)	3.25
"Oritavancin is a novel lipoglycopeptide with demonstrated effectiveness against complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). "	( Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Dunbar, LM; McClure, T; Milata, J; Wasilewski, MM, 2011)	2.08
"Oritavancin is an investigational lipoglycopeptide antibiotic under clinical development for the treatment of gram-positive bacterial infections. "	( In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. Deng, H; Far, AR; Flynn, MA; Keshtgarpour, M; Kumar, A; Mann, HJ; Moriarty, SR; Parr, TR, 2011)	2.1
"Oritavancin is a novel glycopeptide antibiotic with concentration-dependent killing of Gram-positive cocci and pharmacokinetics characterized by extensive tissue distribution and a long terminal half-life. "	( In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Ambrose, PG; Craig, WA; Drusano, GL, 2012)	2.15
"Oritavancin is a semisynthetic lipoglycopeptide analogue of vancomycin that contains the heptapeptide core common to all glycopeptides. "	( Oritavancin: mechanism of action. Karlowsky, JA; Schweizer, F; Zhanel, GG, 2012)	3.26
"Oritavancin is an investigational semisynthetic glycopeptide with potent in vitro activity against VRE (both VanA and VanB phenotypes)."	( Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Arias, CA; Jones, RN; Mendes, RE; Murray, BE; Stilwell, MG, 2012)	1.39
"Oritavancin is a new antibiotic for the treatment of serious infections with Gram-positive bacteria. "	( Oritavancin: a new opportunity for outpatient therapy of serious infections. Tice, A, 2012)	3.26
"Oritavancin is an investigational semisynthetic antibiotic classified as a second-generation lipoglycopeptide, with promising activity against multidrug-resistant gram-positive pathogens."	( Oritavancin: an investigational lipoglycopeptide antibiotic. Chahine, EB; El-Lababidi, R; Karaoui, LR, 2013)	3.28
"Oritavancin (LY333328) is a semisynthetic glycopeptide antibiotic having excellent bactericidal activity against glycopeptide-susceptible and -resistant Gram-positive bacteria. "	( Mechanism of action of oritavancin and related glycopeptide antibiotics. Allen, NE; Nicas, TI, 2003)	2.07
"Oritavancin is a novel glycopeptide currently being developed for the treatment of complicated skin and skin structure infections (cSSSI), including those caused by multidrug resistant gram-positive pathogens. "	( Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Ambrose, PG; Bhavnani, SM; Fetterly, GJ; Loutit, JS; Morello, LG; Nicolau, DP; Ong, CM; Porter, SB, 2005)	2.09
"Oritavancin is a lipoglycopeptide antibiotic with activity against aerobic and anaerobic Gram-positive bacteria. "	( Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens. Crandon, J; Nicolau, DP, 2008)	3.23
"Oritavancin (LY333328) is a new glycopeptide antibiotic with activity against gram-positive organisms; however, there is limited information on the pharmacodynamics of oritavancin with respect to the treatment of S."	( Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Coyle, EA; Rybak, MJ, 2001)	1.41
"Oritavancin (LY333328) is a novel glycopeptide with activity against Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. "	( Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. Mercier, RC; Rybak, MJ; Stumpo, C, 2002)	1.99

Effects

Oritavancin has been shown to have potent in vitro activity against vancomycin-resistant enterococci (VRE) and staphylococci, methicillin-resistant StAPHylococcus aureus (MRSA), and gram-positive anaerobic bacteria. It has been studied in complicated skin and skin structure infections where it was noninferior to the comparator group of van comycin/cephalexin.

Excerpt	Reference	Relevance
"Oritavancin has been shown to have potent in vitro activity against vancomycin-resistant enterococci (VRE) and staphylococci, methicillin-resistant Staphylococcus aureus (MRSA), and gram-positive anaerobic bacteria. "	( Oritavancin: an investigational lipoglycopeptide antibiotic. Chahine, EB; El-Lababidi, R; Karaoui, LR, 2013)	3.28
"Oritavancin has been studied in complicated skin and skin structure infections where it was noninferior to the comparator group of vancomycin/cephalexin."	( Oritavancin: a new avenue for resistant Gram-positive bacteria. Hrebickova, L; Mercier, RC, 2005)	2.49
"Oritavancin has been reported to have activity comparable to that of vancomycin and teicoplanin (Aventis Pharma AG), but retains activity against glycopeptide-resistant bacterial strains [407519]."	( Oritavancin. Eli Lilly & Co. Barrett, JF, 2001)	2.47

Actions

Excerpt	Reference	Relevance
"Oritavancin exhibited lower MIC(50) values (0.03 and 0.5 mg/L) than comparators against methicillin-resistant Staphylococcus aureus (MRSA, n = 50) and vancomycin-intermediate SA strains (n = 60). "	( In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin. Parra-Ruiz, J; Rybak, MJ; Vidaillac, C, 2011)	2.1

Treatment

Oritavancin at ED reduced treatment duration by 0.8 days and led to cost savings of £281.

Excerpt	Reference	Relevance
"Oritavancin at ED reduced treatment duration by 0.8 days and led to cost savings of £281 in comparison to dalbavancin."	( Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective. Falla, E; Mantopoulos, T; Nathwani, D; Vlachaki, I; Zinzi, D, 2022)	1.73
"oritavancin for the treatment of chronic osteomyelitis."	( Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review. Chastain, DB; Davis, A, 2019)	1.49

Toxicity

Excerpt	Reference	Relevance
" Safety and tolerability were evaluated by monitoring adverse events and laboratory parameters."	( Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Ambrose, PG; Bhavnani, SM; Loutit, JS; Owen, JS; Porter, SB, 2004)	0.55
" The frequencies of adverse events were similar among treatment groups."	( Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Dunbar, LM; McClure, T; Milata, J; Wasilewski, MM, 2011)	0.64
" The incidences of adverse events, serious adverse events, and discontinuations due to adverse events were similar for oritavancin (55."	( Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies. Corey, GR; Dudley, MN; Loutit, J; Moeck, G; O'Riordan, W; Wikler, M, 2018)	0.99
" Adverse events (AEs) and mortality were assessed as safety outcomes."	( Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis. Cai, Y; Wang, J; Zhang, H; Zhou, W, 2021)	0.93

Pharmacokinetics

Oritavancin is rapidly distributed to bone tissues, with concentrations remaining stable for up to 168 h, the last measured time point. We utilized an in vitro pharmacodynamic model to compare the activity of oritavANCin to that of vancomycin against two penicillin-, macrolide-, and ciprofloxacin-resistant S. aureus bacteremia.

Excerpt	Reference	Relevance
" Albumin was demonstrated to be almost solely responsible for changes in the aforementioned pharmacodynamic parameters of LY333328."	( Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Hoban, DJ; Kabani, AM; Karlowsky, JA; Kirkpatrick, ID; Zhanel, GG, 1998)	0.3
"The pharmacodynamics of an investigational glycopeptide, LY333328 (LY), alone and in combination with gentamicin, against one vancomycin-susceptible and two vancomycin-resistant Enterococcus faecium strains were studied with a multiple-dose, in vitro pharmacodynamic model (PDM)."	( Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model. Booker, B; Hoban, DJ; Karlowsky, JA; Laing, N; Zelenitsky, SA; Zhanel, GG, 1999)	0.3
"5 g every 12 h) against three of these GISA strains in an in vitro pharmacodynamic infection model."	( Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Aeschlimann, JR; Allen, GP; Hershberger, E; Rybak, MJ, 2000)	0.31
" The mean (range) plasma terminal half-life of oritavancin was 195."	( Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Ambrose, PG; Bhavnani, SM; Loutit, JS; Owen, JS; Porter, SB, 2004)	0.8
" Drug concentrations were determined using a liquid chromatography-tandem mass spectrometry assay and, subsequently, pharmacokinetic analysis was performed."	( Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Ambrose, PG; Bhavnani, SM; Fetterly, GJ; Loutit, JS; Morello, LG; Nicolau, DP; Ong, CM; Porter, SB, 2005)	0.65
" A population pharmacokinetic model was developed to describe the disposition of oritavancin with data from a pooled population of phase 1 healthy subjects and phase 2 and 3 patients with complicated skin and skin structure infections or Staphylococcus aureus bacteremia."	( Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Ambrose, PG; Bhavnani, SM; Forrest, A; McCollam, JS; Rubino, CM; Van Wart, SA, 2009)	2.02
" aureus (MRSA) strain and the antibiotic pharmacodynamic profile against extracellular (broth) and intracellular (human THP-1 monocytes) bacteria."	( Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections. Becker, K; Denis, O; Garcia, LG; Kahl, BC; Lemaire, S; Proctor, RA; Tulkens, PM; Van Bambeke, F, 2012)	0.38
" A total of 1,337 drug concentrations from 297 patients (90% of whom had 4 or 5 pharmacokinetic samples) were available for analysis."	( Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Ambrose, PG; Bellibas, SE; Bhavnani, SM; Moeck, G; Rubino, CM, 2015)	0.65
" The pharmacokinetic profile of oritavancin in rabbits showed that it is rapidly distributed to bone tissues, with concentrations remaining stable for up to 168 h, the last measured time point."	( Oritavancin Pharmacokinetics and Bone Penetration in Rabbits. Belanger, O; Cadieux, C; Far, AR; Lehoux, D; Malouin, M; Ostiguy, V; Parr, TR, 2015)	2.14

Compound-Compound Interactions

Excerpt	Reference	Relevance
"This in vitro study evaluated the activities of vancomycin, LY333328, and teicoplanin alone and in combination with gentamicin, rifampin, and RP59500 against Staphylococcus aureus isolates with intermediate susceptibilities to vancomycin."	( Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by Aeschlimann, JR; Hershberger, E; Moldovan, T; Rybak, MJ, 1999)	0.3
"We investigated the activity of LY333328 alone and combined with gentamicin, both in vitro and in a rabbit model of experimental endocarditis, against the susceptible strain Enterococcus faecalis JH2-2 and its two glycopeptide-resistant transconjugants, BM4316 (VanA) and BM4275 (VanB)."	( Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Carbon, C; Fantin, B; Garry, L; Lefort, A; Saleh-Mghir, A, 2000)	0.31
" This study describes the synergistic activity of oritavancin in combination with gentamicin, linezolid, moxifloxacin, or rifampin in time-kill studies against methicillin-susceptible, vancomycin-intermediate, and vancomycin-resistant Staphylococcus aureus."	( Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Arhin, FF; Belley, A; McKay, GA; Moeck, G; Neesham-Grenon, E; Parr, TR, 2008)	0.84

Bioavailability

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Dosage Studied

Oritavancin has several key features: (i) multiple mechanisms of antibacterial action; (ii) broad spectrum and high potency against Gram-positive pathogens; (iii) bactericidal activity and long duration of the postantibiotic effect. It also has a long half-life, allowing infrequent dosing and potentially allowing the entire course of therapy to be a single dose.

Excerpt	Relevance	Reference
" Single-dose dose-ranging studies suggested a sigmoid maximum effect (E(max)) dose-response relationship, with a maximal effect evident at single doses exceeding 2 mg/kg."	( Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Boylan, CJ; Campanale, K; Iversen, PW; Parr, TR; Phillips, DL; Zeckel, ML, 2003)	0.64
"5- to 3-fold at 24 h following administration of both dosing regimens."	( Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Ambrose, PG; Bhavnani, SM; Fetterly, GJ; Loutit, JS; Morello, LG; Nicolau, DP; Ong, CM; Porter, SB, 2005)	0.65
" It has a long-terminal half-life of 360 h, is highly protein bound and has been dosed once-daily in clinical trials."	( Oritavancin: a new avenue for resistant Gram-positive bacteria. Hrebickova, L; Mercier, RC, 2005)	1.77
" Using classification and regression tree analysis, a breakpoint of the percentage of the dosing interval duration for which free-drug concentrations were above the MIC (free-drug % time > MIC) of 22% was identified for microbiological response; the probabilities of success greater than or equal to and less than this value were 93% and 76%, respectively."	( Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Ambrose, PG; Bhavnani, SM; Loutit, JS; Owen, JS; Passarell, JA; Porter, SB, 2006)	0.57
" The pharmacokinetics and pharmacodynamics of oritavancin appear to be favourable and once-daily dosing is likely."	( Oritavancin--an investigational glycopeptide antibiotic. LaPlante, KL; Mersfelder, TL; Ward, KE, 2006)	2.03
" Although several agents are currently or soon to be available for resistant Gram-positive infections, oritavancin has several key features: (i) multiple mechanisms of antibacterial action; (ii) broad spectrum and high potency against Gram-positive pathogens; (iii) bactericidal activity and long duration of the postantibiotic effect with excellent activity against stationary-phase bacteria and biofilms; (iv) long half-life, allowing infrequent dosing and potentially allowing the entire course of therapy to be a single dose; and (v) documented clinical efficacy and safety."	( Oritavancin for skin infections. Anderson, DL, 2008)	2
" However, the mild nature of the observed relationships for Vc suggest that dosing adjustments are not necessary for elderly patients."	( Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Ambrose, PG; Bhavnani, SM; Forrest, A; McCollam, JS; Rubino, CM; Van Wart, SA, 2009)	1.8
"gov identifier, NCT00514527) of single and infrequent dosing of intravenous (i."	( Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Dunbar, LM; McClure, T; Milata, J; Wasilewski, MM, 2011)	0.64
" However, oritavancin had no substantial growth inhibitory effect against either VISA strain at high inoculum, suggesting that in rare VISA infections with an anticipated high bacterial burden such as endocarditis, alternative oritavancin dosing strategies, including combinations with other agents, may be explored."	( Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus. Arhin, FF; Moeck, G; Parr, TR; Sarmiento, I, 2012)	1.16
" The impact of hemodialysis on plasma concentrations of oritavancin is unknown and may be important in making dosage adjustments in such patients."	( In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. Deng, H; Far, AR; Flynn, MA; Keshtgarpour, M; Kumar, A; Mann, HJ; Moriarty, SR; Parr, TR, 2011)	0.91
" Further clinical studies would be required before making changes in dosage of oritavancin in hemodialysis patients."	( In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. Deng, H; Far, AR; Flynn, MA; Keshtgarpour, M; Kumar, A; Mann, HJ; Moriarty, SR; Parr, TR, 2011)	0.89
" We compared the efficacy of shortened dosing duration (4 days) of oritavancin and vancomycin for CDI treatment using the gut model."	( Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. Chilton, CH; Crowther, GS; Freeman, J; Todhunter, SL; Wilcox, MH, 2012)	0.88
" These data indicate the possible value of a 4 day oritavancin dosing regimen for CDI treatment."	( Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. Chilton, CH; Crowther, GS; Freeman, J; Todhunter, SL; Wilcox, MH, 2012)	0.89
" The dosing schedule of oritavancin eliminates the need for an indwelling catheter and introduces the possibility of avoidance of a hospital admission; although, treatment in non-hospital settings has not been adequately evaluated in clinical trials."	( Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections. Abraham, T; Elnadoury, O; Kuan, W; Lee, S; Liu, M; Truong, J; Wu, A; Wu, G, 2015)	2.17
") dosing offers a potential solution to this burden."	( Oritavancin for acute bacterial skin and skin structure infections. Corey, GR; Fowler, VG; Messina, JA, 2015)	1.86
") dosing offers a potential solution to this burden."	( Oritavancin for acute bacterial skin and skin structure infections. Corey, GR; Fowler, VG; Messina, JA, 2015)	1.86
" The drug is administered as a single intravenous dose of 1200 mg over 3 hours in adult patients, and because of its terminal half-life of 393 hours, repeat dosing is not required in the treatment of ABSSIs."	( Oritavancin: A Long-Half-Life Lipoglycopeptide. Saravolatz, LD; Stein, GE, 2015)	1.86
" Dalbavancin, oritavancin, and tedizolid have been extremely valuable additions to treatment options for ABSSSIs due to the convenient dosing regimen and the fact that there are fewer resistant organisms to these therapies at this time."	( New antibiotics in the management of acute bacterial skin and skin structure infections. Gleghorn, K; Grimshaw, E; Kelly, EK, )	0.49
" Oritavancin offers a number of potential advantages, including a convenient single dose treatment that may shorten or eliminate hospital stays, a reduction in healthcare resource utilization and cost, no need for dosage adjustment in patients with mild to moderate hepatic or renal impairment, no need for therapeutic drug monitoring, and elimination of compliance concerns."	( Oritavancin: a review in acute bacterial skin and skin structure infections. Scott, LJ; Syed, YY, 2015)	2.77
" This addition allows for these agents to have prolonged half-lives, giving them unique dosing profiles."	( Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections. Roberts, KD; Rybak, MJ; Sulaiman, RM, 2015)	0.76
" While telavancin is administered daily at 10 mg/kg, the remarkably long half-lives of oritavancin and dalbavancin allow for infrequent dosing (single dose of 1200 mg for oritavancin and 1000 mg at day 1 followed by 500 mg at day 8 for dalbavancin), which could be exploited in the future for outpatient therapy."	( Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review. Van Bambeke, F, 2015)	0.64
"To review the pharmacology, pharmacokinetics, drug interactions, microbiologic profile, dosage and administration, safety, clinical efficacy, and potential place in therapy for the new lipoglycopetide, oritavancin."	( Oritavancin: A Novel Lipoglycopeptide. Belliveau, P; Durand, C; Mattox, J, 2016)	2.07
" Its reduced dosing and monitoring requirements and efficacy against resistant gram-positive pathogens provide a unique profile that distinguishes it from current options in the treatment of ABSSSI."	( Oritavancin: A Novel Lipoglycopeptide. Belliveau, P; Durand, C; Mattox, J, 2016)	1.88
" Dalbavancin and oritavancin have a long half-life and can be dosed less frequently."	( Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Bassetti, M; Concia, E; Cristini, F; De Rosa, FG; Esposito, S; Menichetti, F; Petrosillo, N; Russo, A; Tumbarello, M; Venditti, M; Viale, P; Viscoli, C, 2016)	0.77
" With a terminal half-life of 8-10 days, oritavancin dosing regimens with infrequent parenteral administration now exist to treat infectious diseases such as osteomyelitis that would otherwise require daily dosing of intravenous antimicrobials for weeks; however, clinical experience is lacking."	( Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin. Darmelio, M; Delaportas, DJ; Estrada, SJ, 2017)	0.94
" Of these, dalbavancin and oritavancin offer extended dosing intervals."	( Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Agarwal, R; Bartsch, SM; Chen, Y; Kelly, BJ; Liu, Y; Prewitt, M; Umscheid, CA, 2018)	0.78

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Role	Description
antibacterial drug	A drug used to treat or prevent bacterial infections.
antimicrobial agent	A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
disaccharide derivative	A carbohydrate derivative that is formally obtained from a disaccharide.
glycopeptide	Any carbohydrate derivative that consists of glycan moieties covalently attached to the side chains of the amino acid residues that constitute the peptide.
semisynthetic derivative	Any organic molecular entity derived from a natural product by partial chemical synthesis.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	24.1500	0.0040	2.9266	9.9600	AID1805801
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	IC50 (µMol)	24.1500	0.0002	2.4585	9.9600	AID1805801
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoesters	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
protein guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (283)

Assay ID	Title	Year	Journal	Article
AID565751	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID520816	Antibacterial activity against Enterococcus faecium clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID565737	Antimicrobial activity against erythromycin-nonsusceptible Streptococcus pyogenes clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID582109	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 10 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID582257	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 50 mg/kg, iv administered as single dose treated 7 days before infection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID457898	Antibacterial activity against Staphylococcus aureus ATCC 13709 in cation adjusted Mueller-Hinton broth by agar diffusion assay in presence of 50% rat serum in absence of polysorbate-80	2010	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4	Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis.
AID545808	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as inhibition of biofilm formation after 24 hrs by serial dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID206645	Antibacterial activity against Methicillin resistant staphylococcus aureus (MRSA)	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Semi-synthetic glycopeptide antibacterials.
AID565743	Antimicrobial activity against Enterococcus faecium expressing VanB gene clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565735	Antimicrobial activity against erythromycin-susceptible Streptococcus Group C clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID1489641	Antibacterial activity against glycopeptide-resistant Enterococcus faecium Efm-HS-0649 vanA after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID560561	Bactericidal activity against vancomycin-resistant Enterococcus faecium 1059060 expressing vanA gene assessed as change in bacterial count at 32 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID560586	Free fraction in healthy human male at 200 mg, iv every 24 hrs by LC/MS/MS analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID581656	Antibacterial activity against revertant Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID582112	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 0.3 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID565731	Antimicrobial activity against erythromycin-nonsusceptible Streptococcus Group G clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID520842	Ratio of MIC for Streptococcus viridans group clinical isolate to MIC for Streptococcus viridans group clinical isolate in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID520821	Antibacterial activity against Streptococcus agalactiae clinical isolate using 2% LHB by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID545815	Antimicrobial activity against 4.6 X 10'6 CFU/peg methicillin-resistant Staphylococcus aureus ATCC 33591 planktonic cells by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID545074	Antimicrobial activity against Enterococcus faecalis clinical isolate A5241515 assessed as septal deformation at 0.12 ug/ml after 3 hrs by transmission electron microscopy	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID565736	Antimicrobial activity against Streptococcus Group C clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID545799	Inhibition of cell division in stationary-phase methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as absence of appearance of septal midline at 1 ug/ml by transmission electron microscopy	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID565753	Antimicrobial activity against oxacillin-resistant Staphylococcus haemolyticus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID546485	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 0.002% polysorbate 80	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID520750	Antibacterial activity against Enterococcus faecalis ATCC 29212 in CAMHB medium by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID1489638	Antibacterial activity against healthcare-associated methicillin-resistant/vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID545816	Antimicrobial activity against 4.6 X 10'6 CFU/peg methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as inhibition of biofilm formation after 24 hrs by serial dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID545587	Bactericidal activity against methicillin-resistant Staphylococcus aureus assessed as log reduction in bacterial load within 15 to 120 mins	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID520833	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in compound MIC by broth microdilution method in presence of 0.002% polysorbate 80 in solvent	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID1728017	Protein binding to human serum albumin	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Polypharmacological drug actions of recently FDA approved antibiotics.
AID520831	Antibacterial activity against Streptococcus Group C clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID520754	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 in CAMHB medium containing 2% LHB by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID560371	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 1058946 by broth dilution method in presence of 4% HSA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID565738	Antimicrobial activity against erythromycin-susceptible Streptococcus pyogenes clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID560354	Cmax in healthy human male at 200 mg, iv every 24 hrs by LC/MS/MS analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID520823	Antibacterial activity against Streptococcus pneumoniae clinical isolate by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID565755	Antimicrobial activity against Staphylococcus haemolyticus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565760	Antimicrobial activity against oxacillin-susceptible Staphylococcus aureus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID581658	Cmax in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID545812	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate VRS5 assessed as inhibition of biofilm formation after 24 hrs by serial dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID582268	Ratio of MIC for Bacillus cereus ATCC 4342 selected after 20 daily cycles of drug selection followed by 5 days of nonselective growth to MIC for Bacillus cereus ATCC 4342	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID560376	Selectivity ratio of MIC for Enterococcus faecalis ATCC 51299 in presence of 4% HSA to MIC for Enterococcus faecalis 51299	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID560369	Antimicrobial activity against vancomycin-resistant Enterococcus faecium ATCC 51559 by broth dilution method in presence of 4% HAS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID520814	Antibacterial activity against Enterococcus faecalis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID520819	Antibacterial activity against coagulase-negative Staphylococcus clinical isolate by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID520827	Antibacterial activity against Streptococcus viridans group clinical isolate by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID546234	Protein binding in human serum by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID582129	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 10 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID582114	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 50 mg/kg, iv administered as single dose treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID584128	Bactericidal activity against heterogeneous vancomycin-intermediate resistant Staphylococcus aureus ATCC 700698 assessed as reduction in bacterial count at 4 ug/ml within 30 mins	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
AID560372	Antimicrobial activity against vancomycin-resistant Enterococcus faecium 1119175 by broth dilution method in presence of 4% HSA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID545595	Bactericidal activity against stationary-phase vancomycin-resistant Staphylococcus aureus isolate VRS5 grown on nutrient-depleted CAMHB medium assessed as log reduction in bacterial count at 0.5 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID565764	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus clinical isolates	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID582110	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 3 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID520829	Antibacterial activity against Streptococcus Group C clinical isolate by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID584126	Increase in membrane permeability in heterogeneous vancomycin-intermediate resistant Staphylococcus aureus ATCC 700698 using SYTO9 staining by fluorimetric assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
AID546475	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 0.002% polysorbate 80 and 95% mouse serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID457894	Antibacterial activity against Streptococcus pneumoniae ATCC 700902 by agar diffusion assay	2010	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4	Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis.
AID565758	Antimicrobial activity against Staphylococcus epidermidis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID581652	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID582262	fAUC (0.25 to 72 hrs) in Bacillus anthracis infected mouse spore inhalation anthrax model at 32 mg/kg, iv administered as single dose	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID545060	Antimicrobial activity against Enterococcus faecalis clinical isolate A5241515 assessed as growth inhibition at 0.12 ug/ml upto 3 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID520815	Antibacterial activity against Enterococcus faecium clinical isolate by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID545805	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate VRS5 planktonic cells by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID520817	Antibacterial activity against Staphylococcus aureus clinical isolate by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID457896	Antibacterial activity against Staphylococcus aureus ATCC 13709 in cation adjusted Mueller-Hinton broth by agar diffusion assay in presence of 50% mouse serum in absence of polysorbate-80	2010	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4	Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis.
AID520812	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 in BHI broth containing 2% LHB by broth microdilution method in absence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID565733	Antimicrobial activity against Streptococcus Group G clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID560367	Antimicrobial activity against vancomycin-resistant Enterococcus faecium 1059060 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID565729	Antimicrobial activity against erythromycin-susceptible Streptococcus Group F clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID545588	Bactericidal activity against stationary-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium assessed as log reduction in bacterial count at 0.5 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID581671	Antibacterial activity against normal phenotype Staphylococcus aureus in cation-adjusted MH 2 broth at pH 5.5 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID582131	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 1 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID565749	Antimicrobial activity against Enterococcus faecalis expressing VanA gene clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565740	Antimicrobial activity against erythromycin-nonsusceptible Streptococcus agalactiae clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565730	Antimicrobial activity against Streptococcus Group F clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID581657	Antibacterial activity against normal phenotype Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID582103	Ratio of MIC90 for Bacillus anthracis in presence of polysorbate-80 to MIC90 for Bacillus anthracis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID582111	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 1 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID565748	Antimicrobial activity against Enterococcus faecalis expressing VanB gene clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565754	Antimicrobial activity against oxacillin-susceptible Staphylococcus haemolyticus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID520820	Antibacterial activity against coagulase-negative Staphylococcus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID208624	Antibacterial activity against Streptococcus pneumoniae	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Semi-synthetic glycopeptide antibacterials.
AID565762	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus clinical isolates	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID520755	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 in CAMHB medium containing 2% LHB by broth microdilution method in absence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID520828	Antibacterial activity against Streptococcus viridans group clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID562357	Antimicrobial activity against Streptococcus pneumoniae clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID546229	Plasma protein binding in human by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID581659	Fraction unbound in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID565752	Antimicrobial activity against Enterococcus faecalis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID582125	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 50 mg/kg, iv administered as single dose treated 14 days before infection measured on 22 days postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID582134	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 50 mg/kg, iv administered as single dose treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID545581	Antimicrobial activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium assessed as membrane depolarization after 30 mins using DiSC3(5) dye based fluorescence spectrophotometry	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID1489642	Antibacterial activity against glycopeptide-resistant Enterococcus faecium Efm-HS-06188 vanA after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID560364	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID581670	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth at pH 5.5 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID581655	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID582265	fAUC (0.25 to 72 hrs) in Bacillus anthracis infected mouse spore inhalation anthrax model at 32 mg/kg, ip administered as single dose	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID565728	Antimicrobial activity against erythromycin-nonsusceptible Streptococcus Group F clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565747	Antimicrobial activity against Enterococcus faecium clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID545798	Bactericidal activity against stationary-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as log reduction in bacterial count at 16 ug/ml within 2 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID565745	Antimicrobial activity against vancomycin-nonsusceptible Enterococcus faecium clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID545070	Antimicrobial activity against Enterococcus faecalis clinical isolate A5241515 assessed as cell ghost formation at 0.12 ug/ml after 3 hrs by transmission electron microscopy	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID560565	Bactericidal activity against vancomycin-resistant Enterococcus faecalis 1058946 expressing vanA gene assessed as change in bacterial count at 2 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID560365	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 1058946 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID565746	Antimicrobial activity against vancomycin-susceptible Enterococcus faecium clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID1728020	Terminal half life in human	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Polypharmacological drug actions of recently FDA approved antibiotics.
AID582259	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 50 mg/kg, iv administered as single dose treated 28 days before infection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID520813	Antibacterial activity against Enterococcus faecalis clinical isolate by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID546232	Plasma protein binding in human at 1 to 91 ug/ml by DCC adsorption method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID546236	Protein binding in dog serum by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID560557	Bactericidal activity against vancomycin-resistant Enterococcus faecium ATCC 51559 expressing vanA gene assessed as change in bacterial count at 32 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID582133	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 0.1 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID520748	Antibacterial activity against Staphylococcus aureus ATCC 29213 in CAMHB medium containing 2% LHB by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID1489645	Antibacterial activity against glycopeptide-resistant Enterococcus faecium Efm-HS-vb01 vanB after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID565741	Antimicrobial activity against erythromycin-susceptible Streptococcus agalactiae clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID545586	Bactericidal activity against vancomycin-resistant Staphylococcus aureus assessed as log reduction in bacterial load within 15 to 120 mins	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID582266	Antimicrobial activity against Bacillus cereus ATCC 4342 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID565759	Antimicrobial activity against oxacillin-resistant Staphylococcus aureus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565756	Antimicrobial activity against oxacillin-resistant Staphylococcus epidermidis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID520822	Antibacterial activity against Streptococcus agalactiae clinical isolate using 2% LHB by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID560558	Bactericidal activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 expressing vanB gene assessed as change in bacterial count at 32 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID560363	Antimicrobial activity against vancomycin-resistant Enterococcus faecium ATCC 51559 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID581666	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID565742	Antimicrobial activity against Streptococcus agalactiae clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565739	Antimicrobial activity against Streptococcus pyogenes clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID457897	Antibacterial activity against Staphylococcus aureus ATCC 13709 in cation adjusted Mueller-Hinton broth by agar diffusion assay in presence of 50% human serum in absence of polysorbate-80	2010	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4	Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis.
AID582267	Antimicrobial activity against Bacillus cereus ATCC 4342 selected after 20 daily cycles of drug selection followed by 5 days of nonselective growth by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID584129	Bactericidal activity against heterogeneous vancomycin-intermediate resistant Staphylococcus aureus ATCC 700698 assessed as reduction in bacterial count at 8 ug/ml within 30 mins	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
AID560564	Bactericidal activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 expressing vanB gene assessed as change in bacterial count at 2 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID562363	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID546231	Plasma protein binding in rat	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID582119	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 10 mg/kg, ip every 48 hrs for 14 days treated 36 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID545073	Antimicrobial activity against Enterococcus faecalis clinical isolate A5241515 assessed as formation of large membrane inclusions at 1 ug/ml after 6 hrs by transmission electron microscopy	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID545797	Bactericidal activity against stationary-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as log reduction in bacterial count at 4 ug/ml within 2 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID545594	Bactericidal activity against stationary-phase methicillin-resistant Staphylococcus aureus ATCC 33591 grown on nutrient-depleted CAMHB medium after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID582264	Tmax in Bacillus anthracis infected mouse spore inhalation anthrax model at 32 mg/kg, ip administered as single dose	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID545582	Antimicrobial activity against stationary-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium assessed as membrane depolarization after 30 mins using DiSC3(5) dye based fluorescence spectrophotometry	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID457895	Antibacterial activity against Staphylococcus aureus ATCC 13709 in cation adjusted Mueller-Hinton broth by agar diffusion assay in absence of polysorbate-80	2010	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4	Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis.
AID560362	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID520841	Ratio of MIC for Streptococcus pyogenes clinical isolate to MIC for Streptococcus pyogenes clinical isolate in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID520844	Ratio of MIC for Streptococcus Group G clinical isolate to MIC for Streptococcus Group G clinical isolate in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID560563	Bactericidal activity against vancomycin-resistant Enterococcus faecium ATCC 51559 expressing vanA gene assessed as change in bacterial count at 2 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID565761	Antimicrobial activity against Staphylococcus aureus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565732	Antimicrobial activity against erythromycin-susceptible Streptococcus Group G clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID562359	Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID560368	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212 by broth dilution method in presence of 4% HSA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID520752	Antibacterial activity against Enterococcus faecalis ATCC 29212 in CAMHB medium containing 2% LHB by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID565750	Antimicrobial activity against vancomycin-nonsusceptible Enterococcus faecalis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID546224	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 0.002% polysorbate 80 and 95% rat serum	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID520824	Antibacterial activity against Streptococcus pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID545790	Antimicrobial activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium assessed as membrane permeability after 30 mins by propidium iodide staining-based fluorescence spectrophotomet	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID520826	Antibacterial activity against Streptococcus pyogenes clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID560562	Bactericidal activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212 assessed as change in bacterial count at 2 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID581661	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID545064	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as aberrant septum formation at 1 ug/ml after 10 mins by transmission electron microscopy	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID545796	Bactericidal activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as log reduction in bacterial count at 4 ug/ml within 2 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID582105	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID584130	Bactericidal activity against heterogeneous vancomycin-intermediate resistant Staphylococcus aureus ATCC 700698 assessed as reduction in bacterial count at 16 ug/ml within 30 mins	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
AID520837	Ratio of MIC for Staphylococcus aureus clinical isolate to MIC for Staphylococcus aureus clinical isolate in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID520756	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 in BHI broth by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID546226	Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% mouse serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% mouse serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID582260	Free peak concentration in Bacillus anthracis infected mouse spore inhalation anthrax model at 32 mg/kg, iv administered as single dose	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID520747	Antibacterial activity against Staphylococcus aureus ATCC 29213 in CAMHB medium by broth microdilution method in absence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID546245	Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% human serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% human serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID520830	Antibacterial activity against Streptococcus Group G clinical isolate by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID584135	Antimicrobial activity against vancomycin-resistant Enterococcus	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
AID584136	Antimicrobial activity against heterogeneous vancomycin-intermediate resistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
AID581665	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID520835	Ratio of MIC for Enterococcus faecalis clinical isolate to MIC for Enterococcus faecalis clinical isolate in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID584124	Induction of membrane depolarization in heterogeneous vancomycin-intermediate resistant Staphylococcus aureus ATCC 700698 using DiSC3(5) dye by fluorimetric assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
AID582263	Free peak concentration in Bacillus anthracis infected mouse spore inhalation anthrax model at 32 mg/kg, ip administered as single dose	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID520818	Antibacterial activity against Staphylococcus aureus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID560566	Bactericidal activity against vancomycin-resistant Enterococcus faecium 1119175 expressing vanB gene assessed as change in bacterial count at 2 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID582139	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 10 mg/kg, ip every 48 hrs for 14 days treated 36 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID546227	Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% rat serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% rat serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID545061	Antimicrobial activity against Enterococcus faecalis clinical isolate A5241515 assessed as growth inhibition at 1 ug/ml upto 6 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID582104	Antimicrobial activity against Bacillus anthracis Ames by broth microdilution method in presence of polysorbate-80	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID562361	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565763	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus clinical isolates	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID560366	Antimicrobial activity against vancomycin-resistant Enterococcus faecium 1119175 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID1489637	Antibacterial activity against vancomycin/methicillin-susceptible Staphylococcus aureus Newman ATCC 5904 after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID520825	Antibacterial activity against Streptococcus pyogenes clinical isolate by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID581664	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID560358	Cmin in healthy human male at 200 mg, iv every 24 hrs by LC/MS/MS analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID582123	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 50 mg/kg, iv administered as single dose treated 24 hrs before infection measured on 33 days postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID581667	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level after 24 hrs in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID565734	Antimicrobial activity against erythromycin-nonsusceptible Streptococcus Group C clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID545789	Antimicrobial activity against stationary-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium assessed as membrane permeability after 30 mins by propidium iodide staining-based fluorescence spectrophotometr	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID560567	Bactericidal activity against vancomycin-resistant Enterococcus faecium 1059060 expressing vanA gene assessed as change in bacterial count at 2 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID545810	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as inhibition of biofilm formation after 24 hrs by serial dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID565757	Antimicrobial activity against oxacillin-susceptible Staphylococcus epidermidis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID520843	Ratio of MIC for Streptococcus Group C clinical isolate to MIC for Streptococcus Group C clinical isolate in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID582102	Antimicrobial activity against Bacillus anthracis by broth microdilution method in presence of polysorbate-80	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID560559	Bactericidal activity against vancomycin-resistant Enterococcus faecalis 1058946 expressing vanA gene assessed as change in bacterial count at 32 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID546487	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 0.002% polysorbate 80 and 95% human serum	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID520838	Ratio of MIC for coagulase-negative Staphylococcus clinical isolate to MIC for coagulase-negative Staphylococcus clinical isolate in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID581663	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID582115	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 15 mg/kg, iv administered as single dose treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID546233	Binding affinity to human serum albumin at 0.2 ug/ml	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID67342	Antibacterial activity against Enterococcus species., VanA	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Semi-synthetic glycopeptide antibacterials.
AID545591	Bactericidal activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium at 0.5 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID581660	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU after 5 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID545058	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as reduction in cell counts at 1 ug/ml after 10 mins	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID520836	Ratio of MIC for Enterococcus faecium clinical isolate to MIC for Enterococcus faecium clinical isolate in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID584132	Antimicrobial activity against heterogeneous vancomycin-intermediate resistant Staphylococcus aureus ATCC 700698	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
AID582113	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 0.1 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID546476	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 0.002% polysorbate 80 and 95% mouse serum	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID582135	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 15 mg/kg, iv administered as single dose treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID545593	Bactericidal activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium at 4 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID443659	Antibacterial activity against vancomycin and teicoplanin-resistant Enterococcus harboring vanA resistance gene	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID545592	Bactericidal activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium at 16 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID1489644	Antibacterial activity against glycopeptide-resistant Enterococcus faecium Efm-HS-08257 vanM after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID560375	Selectivity ratio of MIC for Enterococcus faecium ATCC 51559 in presence of 4% HSA to MIC for Enterococcus faecium ATCC 51559	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID565744	Antimicrobial activity against Enterococcus faecium expressing VanA gene clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID545071	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as cell wall thickening at 1 ug/ml after 10 mins by transmission electron microscopy	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID545803	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 planktonic cells by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID582141	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 50 mg/kg, iv administered as single dose treated 42 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID560556	Bactericidal activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212 assessed as change in bacterial count at 32 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID582271	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 0.1 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection measured on day 3	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID584133	Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
AID520753	Antibacterial activity against Enterococcus faecalis ATCC 29212 in CAMHB medium containing 2% LHB by broth microdilution method in absence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID560377	Selectivity ratio of MIC for Enterococcus faecalis 1058946 in presence of 4% HSA to MIC for Enterococcus faecalis 1058946	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID520758	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 in BHI broth containing 2% LHB by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID560373	Antimicrobial activity against vancomycin-resistant Enterococcus faecium 1059060 by broth dilution method in presence of 4% HSA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID542350	Antimicrobial activity against Enterococcus faecalis clinical isolate A5241515 assessed as formation of extensive fibrils around the cell at 0.12 ug/ml after 3 hrs by transmission electron microscopy	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID546228	Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% dog serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% dog serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID560374	Selectivity ratio of MIC for Enterococcus faecalis ATCC 29212 in presence of 4% HSA to MIC for Enterococcus faecalis ATCC 29212	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID545062	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as septal deformation at 1 ug/ml after 10 mins by transmission electron microscopy	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID546230	Protein binding in mouse serum by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID582124	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 50 mg/kg, iv administered as single dose treated 7 days before infection measured on 33 days postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID520834	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in compound MIC by broth microdilution method in presence of 0.002% polysorbate 80 in inoculum	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID545068	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as formation of membrane inclusions at 1 ug/ml after 10 mins by transmission electron microscopy	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID545795	Bactericidal activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as log reduction in bacterial count at 16 ug/ml within 15 mins by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID520757	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 in BHI broth by broth microdilution method in absence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID582128	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 30 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID546486	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 0.002% polysorbate 80 and 95% human serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID581654	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in absence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID560379	Selectivity ratio of MIC for Enterococcus faecium 1059060 in presence of 4% HSA to MIC for Enterococcus faecium 1059060	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID582108	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 30 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID584134	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
AID582132	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 0.3 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID545807	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as inhibition of bacterial biofilm formation after 1 hr by serial dilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID207006	Antibacterial activity against Vancomycin resistant staphylococcus aureus (VRSA)	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Semi-synthetic glycopeptide antibacterials.
AID545801	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 planktonic cells by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID545814	Bactericidal activity against stationary-phase vancomycin-resistant Staphylococcus aureus isolate VRS5 after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID582120	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 10 mg/kg, ip every 48 hrs for 14 days treated 48 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID520840	Ratio of MIC for Streptococcus pneumoniae clinical isolate to MIC for Streptococcus pneumoniae clinical isolate in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID565765	Antimicrobial activity against vancomycin- susceptible Staphylococcus aureus clinical isolates	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID545788	Bactericidal activity against stationary-phase methicillin-resistant Staphylococcus aureus ATCC 33591 grown on nutrient-depleted CAMHB medium assessed as reduction in bacterial count at 0.5 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID520832	Antibacterial activity against Streptococcus Group G clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID582106	fAUC (0 to 48 hrs ) in mouse anthrax model at 1.2 mg/kg, ip by LS/MS method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID546242	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 0.002% polysorbate 80 and 95% dog serum	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID560560	Bactericidal activity against vancomycin-resistant Enterococcus faecium 1119175 expressing vanB gene assessed as change in bacterial count at 32 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID520746	Antibacterial activity against Staphylococcus aureus ATCC 29213 in CAMHB medium by broth microdilution method in presence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID582256	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 50 mg/kg, iv administered as single dose treated 24 hrs before infection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID582258	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 50 mg/kg, iv administered as single dose treated 14 days before infection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID582261	Tmax in Bacillus anthracis infected mouse spore inhalation anthrax model at 32 mg/kg, iv administered as single dose	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID520751	Antibacterial activity against Enterococcus faecalis ATCC 29212 in CAMHB medium by broth microdilution method in absence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID545585	Bactericidal activity against methicillin-sensitive Staphylococcus aureus assessed as log reduction in bacterial load within 15 to 120 mins	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID520749	Antibacterial activity against Staphylococcus aureus ATCC 29213 in CAMHB medium containing 2% LHB by broth microdilution method in absence of 0.002% polysorbate 80	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
AID545066	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as loss of septal midline at 1 ug/ml after 10 mins by transmission electron microscopy	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
AID582140	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 10 mg/kg, ip every 48 hrs for 14 days treated 48 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID560370	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 by broth dilution method in presence of 4% HSA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID1489643	Antibacterial activity against glycopeptide-resistant Enterococcus faecium Efm-HS-0847 vanM after 24 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
AID582121	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 50 mg/kg, iv administered as single dose treated 42 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID582126	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 50 mg/kg, iv administered as single dose treated 28 days before infection measured on 22 days postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID582130	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 3 mg/kg, ip every 48 hrs for 14 days treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID582116	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as survival rate at 5 mg/kg, iv administered as single dose treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID546235	Protein binding in rat serum by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID545817	fCmin in human at 200 mg/kg	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID546481	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 0.002% polysorbate 80 and 95% rat serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID581662	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU after 72 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID546241	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 0.002% polysorbate 80 and 95% dog serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID582136	Antimicrobial activity against Bacillus anthracis infected mouse spore inhalation anthrax model assessed as bacterial load per gram of lung tissue at 5 mg/kg, iv administered as single dose treated 24 hrs postinfection	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1805801	Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	24 (10.00)	18.2507
2000's	65 (27.08)	29.6817
2010's	129 (53.75)	24.3611
2020's	22 (9.17)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	11 (4.49%)	5.53%
Reviews	58 (23.67%)	6.00%
Case Studies	5 (2.04%)	4.05%
Observational	2 (0.82%)	0.25%
Other	169 (68.98%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Trial	Phase	Enrollment	Study Type	Start Date	Status
Anchoring Intermittent Long Acting Antimicrobials to Medication for Opioid Use Disorder Treatment to Facilitate Structured Transitions of Care for People Who Use Drugs Admitted to the Hospital With Invasive Infections [NCT05521880]	Phase 4	25 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]	Phase 4	135 participants (Anticipated)	Interventional	2023-08-04	Enrolling by invitation
A Randomized, Open-label, PK and Safety Study to Evaluate the Relative Exposure and Safety of a New Formulation vs the Approved Formulation of a Single 1200 mg IV Dose of ORBACTIV® (Oritavancin) in Subjects Being Treated for ABSSSI [NCT03873987]	Phase 1	102 participants (Actual)	Interventional	2019-07-16	Completed
An Open-Label Study to Evaluate the Safety of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) in Subjects on Concomitant Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI) [NCT02452918]	Phase 4	17 participants (Actual)	Interventional	2015-09-29	Completed
A Pilot Proof of Concept Single-Center Study of the Use of Oritavancin in Systemic Staphylococcus Aureus Infections in Patients With Opioid Use Disorder [NCT03761953]	Phase 4	0 participants (Actual)	Interventional	2019-07-01	Withdrawn(stopped due to COVID 19 pandemic)
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS) [NCT02134301]	Phase 1	52 participants (Anticipated)	Interventional	2014-05-31	Recruiting
A Double-Blind, Randomized Study to Evaluate the Safety of Either a Single 1200-mg Intravenous (IV) Dose of Orbactiv™ (Oritavancin) and Placebo or Two IV Doses of Orbactiv™ in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection (A [NCT02925416]	Phase 4	22 participants (Actual)	Interventional	2017-01-31	Completed
An Open-Label Study to Assess the Drug-Drug Interaction Potential of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects. [NCT02340988]	Phase 1	36 participants (Actual)	Interventional	2015-04-30	Completed
Nuvocid® (Oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI) [NCT00514527]	Phase 2	294 participants (Anticipated)	Interventional	2007-08-31	Completed
A Randomized, Double-Blind, Single Center Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of a Single 1200MG IV Dose of Oritavancin in Healthy Volunteers [NCT02471690]	Phase 1	56 participants (Actual)	Interventional	2015-07-31	Completed
A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin Infusions in Healthy Subjects [NCT02470702]	Phase 1	14 participants (Actual)	Interventional	2015-06-30	Completed
A Single Center, Open-label Study to Evaluate the Effects of a Single 1200mg IV Dose of Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers [NCT02357524]	Phase 1	20 participants (Actual)	Interventional	2015-01-31	Completed
Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail [NCT01784536]	Phase 1	16 participants (Actual)	Interventional	2013-01-31	Completed
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Design, Study With an Open-Label Positive-Control, to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers [NCT01762839]	Phase 1	150 participants (Actual)	Interventional	2013-01-31	Completed
A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II) [NCT01252732]	Phase 3	1,019 participants (Actual)	Interventional	2010-12-31	Completed
A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin vs SoC for the Treatment of Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections [NCT05599295]	Phase 2	200 participants (Anticipated)	Interventional	2023-06-15	Recruiting
A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO I) [NCT01252719]	Phase 3	968 participants (Actual)	Interventional	2010-12-31	Completed
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting [NCT03159403]		325 participants (Actual)	Observational	2017-04-12	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial	Outcome
NCT01252719 (3) [back to overview]	Cessation Of Spread Or Reduction In Size Of Baseline Lesion, Absence Of Fever, And No Rescue Antibiotic Medication At Early Clinical Evaluation (ECE) (48 To 72 Hours)
NCT01252719 (3) [back to overview]	Investigator Assessed Clinical Cure Of Treatment With Single-dose IV Oritavancin Compared With IV Vancomycin For 7 To 10 Days At Post-therapy Evaluation (Key Secondary Endpoint)
NCT01252719 (3) [back to overview]	Number Of Participants With A Lesion Size Reduction ≥20% From Baseline At ECE
NCT01252732 (3) [back to overview]	>= 20% Reduction in Lesion Area
NCT01252732 (3) [back to overview]	Early Clinical Response
NCT01252732 (3) [back to overview]	Investigator Assessed Clinical Cure at Post Therapy Evaluation (Key Secondary Endpoint)
NCT02452918 (2) [back to overview]	Number of Participants With a Clinical Response of Cure
NCT02452918 (2) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03873987 (3) [back to overview]	Number of Subjects With at Least One Treatment Emergent Adverse Event (TEAE)
NCT03873987 (3) [back to overview]	Relative Exposure of AUC of the New Formulation to the Approved Formulation
NCT03873987 (3) [back to overview]	Relative Exposure of AUC of the New Formulation to the Approved Formulation

Intervention	participants (Number)
	Success	Failure
Single-Dose 1200 mg Oritavancin	391	84
Vancomycin	378	101

Intervention	participants (Number)
	Clinical Cure	Clinical Failure
Single-Dose 1200 mg Oritavancin	378	97
Vancomycin	383	96

Intervention	Participants (Count of Participants)
	Success	Failure
Single-Dose 1200 mg Oritavancin	413	62
Vancomycin	397	82

Intervention	participants (Number)
	Success	Failure
Single-Dose 1200 mg Oritavancin	432	71
Vancomycin	428	74

Intervention	participants (Number)
	Success	Failure
Single-Dose 1200 mg Oritavancin	403	100
Vancomycin	416	86

Intervention	participants (Number)
	Clinical Cure	Clinical Failure
Single-Dose 1200 mg Oritavancin	416	87
Vancomycin	404	98

Intervention	Participants (Count of Participants)
Oritavancin 1200 mg Without Concomitant Warfarin Therapy	15
Oritavancin 1200 mg With Concomitant Warfarin Therapy	2

Intervention	Participants (Count of Participants)
	At least 1 AE	At least 1 SAE
Oritavancin 1200 mg With Concomitant Warfarin Therapy	1	0
Oritavancin 1200 mg Without Concomitant Warfarin Therapy	2	0

Intervention	Participants (Count of Participants)
Orbactiv	31
Kimyrsa	24

Intervention	h*µg/mL (Geometric Mean)
Orbactiv	1760
Kimrysa	1750

Intervention	h*µg/mL (Geometric Least Squares Mean)
Orbactiv	1470
Kimrysa	1460

Substance	Relationship Strength	Studies	Trials	Classes	Roles
aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.	2.6	1	0	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite
coumarin 2H-chromen-2-one: coumarin derivative	2.6	1	0	coumarins	fluorescent dye; human metabolite; plant metabolite
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	2.6	1	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
alanylalanine alanylalanine: RN given refers to (DL)-isomer	2.15	1	0	dipeptide
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.01	1	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
thioctic acid Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.	2.6	1	0	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector
picolinic acid picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206. picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.	2.6	1	0	pyridinemonocarboxylic acid	human metabolite; MALDI matrix material
thiamine thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.	2.6	1	0	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
catechin [no description available]	2.31	1	0	hydroxyflavan
5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate [no description available]	2.31	1	0	catechin
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	2.05	1	0	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
3-aminobenzamide [no description available]	2.6	1	0	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pleconaril WIN 63843: structure given in first source	2.6	1	0
4-(2-aminoethyl)benzenesulfonylfluoride [no description available]	2.6	1	0
phenytoin [no description available]	2.6	1	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	2.6	1	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	2.6	1	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	2.53	2	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
theophylline [no description available]	2.31	1	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
2-aminothiazole 2-aminothiazole: RN given refers to parent cpd; structure. 1,3-thiazol-2-amine : A primary amino compound that is 1,3-thiazole substituted by an amino group at position 2.	2.6	1	0	1,3-thiazoles; primary amino compound
amodiaquine Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.. amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.	2.6	1	0	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	2.6	1	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
baclofen [no description available]	2.6	1	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
benzamide benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.	2.6	1	0	benzamides
bronopol [no description available]	2.31	1	0	nitro compound
caffeine [no description available]	2.31	1	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
N-[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]carbamic acid (phenylmethyl) ester [no description available]	2.31	1	0	leucine derivative
camostat camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.	2.6	1	0	benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor
camphor, (+-)-isomer [no description available]	2.6	1	0	bornane monoterpenoid; cyclic monoterpene ketone	plant metabolite
candesartan candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.	2.6	1	0	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
carmofur [no description available]	2.31	1	0	organohalogen compound; pyrimidines
cetylpyridinium Cetylpyridinium: Cationic bactericidal surfactant used as a topical antiseptic for skin, wounds, mucous membranes, instruments, etc.; and also as a component in mouthwash and lozenges.	2.6	1	0	pyridinium ion
chloroxylenol chloroxylenol: topical antiseptic; RN given refers to parent cpd; structure. 4-chloro-3,5-dimethylphenol : A member of the class of phenols that is 3,5-xylenol which is substituted at position 4 by chlorine. It is bactericidal against most Gram-positive bacteria but less effective against Staphylococci and Gram-negative bacteria, and often inactive against Pseudomonas species. It is ineffective against bacterial spores.	2.6	1	0	monochlorobenzenes; phenols	antiseptic drug; disinfectant; molluscicide
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	2.6	1	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
ciprofibrate [no description available]	2.6	1	0	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	3.54	8	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	2.6	1	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
danthron danthron: structure. chrysazin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8.	2.6	1	0	dihydroxyanthraquinone	apoptosis inducer; plant metabolite
deferiprone Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.	2.6	1	0	4-pyridones	iron chelator; protective agent
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	2.6	1	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disulfiram [no description available]	2.82	2	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	2.6	1	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
doxazosin Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.	2.6	1	0	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent
ebselen ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.	2.82	2	0	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.	2.6	1	0	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
2-hexyloxybenzamide 2-hexyloxybenzamide: structure	2.6	1	0	aromatic ether; benzamides	antifungal agent
brl 42810 [no description available]	2.6	1	0	2-aminopurines; acetate ester	antiviral drug; prodrug
fluphenazine [no description available]	2.6	1	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.6	1	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
gabexate Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.	2.6	1	0	benzoate ester
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	3.8	11	0
glutaral Glutaral: One of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.. glutaraldehyde : A dialdehyde comprised of pentane with aldehyde functions at C-1 and C-5.	2.6	1	0	dialdehyde	cross-linking reagent; disinfectant; fixative
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	2.6	1	0	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.6	1	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
hexachlorophene Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.	2.31	1	0	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	2.6	1	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
hexylresorcinol [no description available]	2.6	1	0	resorcinols
beta-thujaplicin beta-thujaplicin: structure. beta-thujaplicin : A monoterpenoid that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2 and an isopropyl group at position 4. Isolated from Thuja plicata and Chamaecyparis obtusa, it exhibits antimicrobial activities.	2.6	1	0	cyclic ketone; enol; monoterpenoid	antibacterial agent; antifungal agent; antineoplastic agent; antiplasmodial drug; plant metabolite
hycanthone Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.	2.6	1	0	thioxanthenes	mutagen; schistosomicide drug
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	2.6	1	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	2.31	1	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
hydroxyurea [no description available]	2.6	1	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	2.6	1	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.6	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	2.6	1	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
itraconazole [no description available]	2.6	1	0	piperazines
kojic acid [no description available]	2.6	1	0	4-pyranones; enol; primary alcohol	Aspergillus metabolite; EC 1.10.3.1 (catechol oxidase) inhibitor; EC 1.10.3.2 (laccase) inhibitor; EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; EC 1.4.3.3 (D-amino-acid oxidase) inhibitor; NF-kappaB inhibitor; skin lightening agent
lapachol lapachol : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. It is a natural compound that exhibits antibacterial and anticancer properties, first isolated in 1882 from the bark of Tabebuia avellanedae.	2.6	1	0
beta-lapachone beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.	2.31	1	0	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite
loperamide Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	2.6	1	0	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	2.6	1	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	2.6	1	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide: structure in first source. 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide : A benzamide resulting from the formal condensation of the carboxy group of 4-(dimethylamino)benzoic acid with the amino group of 7-amino-N-hydroxyheptanamide. It is a potent inhibitor of histone deacetylases and induces cell cycle arrest and apoptosis in several human cancer cell lines.	2.6	1	0	benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
mafenide Mafenide: A sulfonamide that inhibits the enzyme CARBONIC ANHYDRASE and is used as a topical anti-bacterial agent, especially in burn therapy.	2.6	1	0	aromatic amine
vitamin k 3 Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.	2.54	2	0	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
methazolamide Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.	2.6	1	0	sulfonamide; thiadiazoles
methocarbamol Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.	2.6	1	0	aromatic ether; carbamate ester; secondary alcohol
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	2.04	1	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	2.6	1	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
entinostat [no description available]	2.6	1	0	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
ethylmaleimide Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.	2.6	1	0	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
nabumetone Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.	2.6	1	0	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
nafamostat nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic	2.6	1	0	benzoic acids; guanidines
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.6	1	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
niclosamide Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.	2.31	1	0	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	2.6	1	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
osalmide osalmide: structure	2.6	1	0	organic molecular entity
oxethazaine [no description available]	2.6	1	0	amino acid amide
palmidrol palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.	2.6	1	0	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	2.6	1	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pentoxifylline [no description available]	2.6	1	0	oxopurine
perhexiline Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.	2.6	1	0	piperidines	cardiovascular drug
phenazopyridine Phenazopyridine: A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.. phenazopyridine : A diaminopyridine that is 2,6-diaminopyridine substituted at position 3 by a phenylazo group. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.	2.6	1	0	diaminopyridine; monoazo compound	anticoronaviral agent; carcinogenic agent; local anaesthetic; non-narcotic analgesic
4-phenylbutyric acid 4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.	2.6	1	0	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
phenylmethylsulfonyl fluoride Phenylmethylsulfonyl Fluoride: An enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex.. phenylmethanesulfonyl fluoride : An acyl fluoride with phenylmethanesulfonyl as the acyl group.	2.6	1	0	acyl fluoride	serine proteinase inhibitor
pimobendan pimobendan: produces arterial & venous dilatation in dogs; structure given in first source	2.6	1	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
pj-34 PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties.	2.6	1	0	phenanthridines; secondary carboxamide; tertiary amino compound	angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent
praziquantel azinox: Russian drug	2.6	1	0	isoquinolines
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	2.6	1	0	benzoic acids; sulfonamide	uricosuric drug
probucol Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.	2.6	1	0	dithioketal; polyphenol	anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug
promazine Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.	2.6	1	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	2.6	1	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.6	1	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protoporphyrin ix protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685. protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.	2.31	1	0
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one [no description available]	2.31	1	0	indoles
rimantadine Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.	2.53	2	0	alkylamine
rolipram [no description available]	2.6	1	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
scriptaid scriptide: provokes translocation of GLUT4 to increase glucose uptake; structure in first source	2.6	1	0	isoquinolines
sebacic acid sebacic acid : An alpha,omega-dicarboxylic acid that is the 1,8-dicarboxy derivative of octane.	2.6	1	0	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	human metabolite; plant metabolite
alkannin [no description available]	2.31	1	0	naphthoquinone
fenofibrate [no description available]	2.6	1	0	benzochromenone; delta-lactone; naphtho-alpha-pyrone	platelet aggregation inhibitor; Sir2 inhibitor
imatinib [no description available]	2.6	1	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.	2.03	1	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
suprofen Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.	2.6	1	0	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	2.6	1	0	phthalimides; piperidones
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	2.6	1	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	2.6	1	0	pteridines	diuretic; sodium channel blocker
triclosan [no description available]	2.31	1	0	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
trifluoperazine [no description available]	2.6	1	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
triflupromazine Triflupromazine: A phenothiazine used as an antipsychotic agent and as an antiemetic.. triflupromazine : A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position.	2.6	1	0	organofluorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; first generation antipsychotic
trigonelline trigonelline: in hydra among other organisms; RN given refers to hydroxide inner salt; structure. N-methylnicotinic acid : A pyridinium ion consisting of nicotinic acid having a methyl substituent on the pyridine nitrogen.. N-methylnicotinate : An iminium betaine that is the conjugate base of N-methylnicotinic acid, arising from deprotonation of the carboxy group.	2.6	1	0	alkaloid; iminium betaine	food component; human urinary metabolite; plant metabolite
trimethobenzamide trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd. trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.	2.6	1	0	benzamides; tertiary amino compound	antiemetic
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.83	3	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
tyrphostin a9 [no description available]	2.6	1	0	alkylbenzene	geroprotector
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	2.6	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
vesnarinone [no description available]	2.6	1	0	organic molecular entity
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2.77	3	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
idoxuridine [no description available]	2.6	1	0	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	3.93	3	0	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	2.6	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	3.71	2	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	3.19	1	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
phenylethyl alcohol Phenylethyl Alcohol: An antimicrobial, antiseptic, and disinfectant that is used also as an aromatic essence and preservative in pharmaceutics and perfumery.. 2-phenylethanol : A primary alcohol that is ethanol substituted by a phenyl group at position 2.	2.6	1	0	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	7.76	3	0	penicillin allergen; penicillin	antibacterial drug
zoxazolamine Zoxazolamine: A uricosuric and muscle relaxant. Zoxazolamine acts centrally as a muscle relaxant, but the mechanism of its action is not understood.	2.6	1	0	benzoxazole
oxacillin Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.	2.77	3	0	penicillin	antibacterial agent; antibacterial drug
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.6	1	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
ficusin Ficusin: A naturally occurring furocoumarin, found in PSORALEA. After photoactivation with UV radiation, it binds DNA via single and double-stranded cross-linking.. psoralen : The simplest member of the class of psoralens that is 7H-furo[3,2-g]chromene having a keto group at position 7. It has been found in plants like Psoralea corylifolia and Ficus salicifolia.	2.6	1	0	psoralens	plant metabolite
tubercidin Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.	2.6	1	0	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; ribonucleoside	antimetabolite; antineoplastic agent; bacterial metabolite
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	8.12	5	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
trifluridine Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.	2.6	1	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor
9,10-anthraquinone 9,10-anthraquinone : An anthraquinone that is anthracene in which positions 9 and 10 have been oxidised to carbonyls.	2.6	1	0	anthraquinone
salicylanilide salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide.	2.6	1	0	benzanilide fungicide; salicylamides; salicylanilides
gramine gramine : An aminoalkylindole that is indole carrying a dimethylaminomethyl substituent at postion 3.	2.6	1	0	aminoalkylindole; indole alkaloid; tertiary amino compound	antibacterial agent; antiviral agent; plant metabolite; serotonergic antagonist
pyromellitic acid pyromellitic acid: RN given refers to parent cpd; structure. pyromellitic acid : A tetracarboxylic acid that is benzene substituted by four carboxy groups at positions 1, 2, 4 and 5 respectively.	2.31	1	0	benzoic acids; tetracarboxylic acid
aminacrine Aminacrine: A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.. 9-aminoacridine : An aminoacridine that is acridine in which the hydrogen at position 9 is replaced by an amino group. A fluorescent dyd and topical antiseptic agent, it is used (usually as the hydrochloride salt) in eye drops for the treatment of superficial eye infections.	2.6	1	0	aminoacridines; primary amino compound	acid-base indicator; antiinfective agent; antiseptic drug; fluorescent dye; MALDI matrix material; mutagen
methyl gallate methyl gallate: has both immunosuppressive and phytogenic antineoplastic activities; isolated from Acer saccharinum. methyl 3,4,5-trihydroxybenzoate : A gallate ester obtained by the formal condensation of gallic acid with methanol. It exhibits anti-oxidant, anti-tumor, anti-microbial and anti-inflammatory properties.	2.6	1	0	gallate ester	anti-inflammatory agent; antioxidant; plant metabolite
monobenzone monobenzone: structure. monobenzone : The monobenzyl ether of hydroquinone. It is used as a topical drug for medical depigmentation.	2.6	1	0	benzyl ether	allergen; dermatologic drug; melanin synthesis inhibitor
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	3.15	1	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
chloranil Chloranil: A quinone fungicide used for treatment of seeds and foliage.. tetrachloro-1,4-benzoquinone : A member of the class of 1,4-benzoquiones that is 1,4-benzoquinone in which all four hydrogens are substituted by chlorines.	2.31	1	0	1,4-benzoquinones; organochlorine compound	EC 2.7.1.33 (pantothenate kinase) inhibitor; metabolite
nafcillin Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.	2.13	1	0	penicillin allergen; penicillin	antibacterial drug
ditiocarb Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.	2.6	1	0	dithiocarbamic acids	chelator; copper chelator
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	2.6	1	0	catechin	antioxidant; plant metabolite
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	4.98	6	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	3.15	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	2.6	1	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
lucanthone Lucanthone: One of the SCHISTOSOMICIDES, it has been replaced largely by HYCANTHONE and more recently PRAZIQUANTEL. (From Martindale The Extrapharmacopoeia, 30th ed., p46). lucanthone : A thioxanthen-9-one compound having a methyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. Formerly used for the treatment of schistosomiasis. It is a prodrug, being metabolised to hycanthone.	2.6	1	0	thioxanthenes	adjuvant; antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; mutagen; photosensitizing agent; prodrug; schistosomicide drug
plumbagin plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.	2.31	1	0	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite
cepharanthine cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation.	2.6	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
aloe emodin aloe emodin: structure distinct from emodin; this does not mean emodin from aloe. Aloe emodin : A dihydroxyanthraquinone that is chrysazin carrying a hydroxymethyl group at position 3. It has been isolated from plant species of the genus Aloe.	2.6	1	0	aromatic primary alcohol; dihydroxyanthraquinone	antineoplastic agent; plant metabolite
chrysophanic acid chrysophanic acid: RN given refers to parent cpd; structure in Merck, 9th ed, #2260. chrysophanol : A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.	2.6	1	0	dihydroxyanthraquinone	anti-inflammatory agent; antiviral agent; plant metabolite
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.6	1	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
osthol osthol: from Cnidium monnieri and Angelica pubescens (both Apiaceae); structure given in first source	2.6	1	0	botanical anti-fungal agent; coumarins	metabolite
flavanone flavanone: RN given refers to cpd with unspecified isomeric designation; structure in first source. flavanone : The simplest member of the class of flavanones that consists of flavan bearing an oxo substituent at position 4.	2.6	1	0	flavanones
dithiol dithiol: structure	2.31	1	0
phloretic acid phloretic acid: structure. N-hydroxysuccinimide ester : An ester of N-hydroxysuccinimide.. phloretic acid : A hydroxy monocarboxylic acid consisting of propionic acid having a 4-hydroxyphenyl group at the 3-position.	2.6	1	0	hydroxy monocarboxylic acid	plant metabolite
oleanolic acid [no description available]	2.6	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
dihydroergotamine Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.	2.31	1	0	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
abietic acid abietic acid : An abietane diterpenoid that is abieta-7,13-diene substituted by a carboxy group at position 18.	2.31	1	0	abietane diterpenoid; monocarboxylic acid	plant metabolite
angelicin angelicin: used as tranquillizer; sedative; or anticonvulsant; structure	2.6	1	0	furanocoumarin
diperodon diperodon: RN given refers to parent cpd; structure given in first source	2.6	1	0	carbamate ester
megestrol acetate [no description available]	2.6	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.6	1	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
4-(dimethylamino)benzoic acid [no description available]	2.31	1	0
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.45	2	0	cyclic ketone; erythromycin
agaric acid agaric acid: adenine nucleotide translocase antagonist	2.31	1	0
hydroxychloroquine sulfate [no description available]	2.6	1	0
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	2.6	1	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
metformin hydrochloride metformin hydrochloride : A hydrochloride resulting from the reaction of metformin with one molar equivalent of hydrogen chloride.	2.6	1	0	hydrochloride	environmental contaminant; hypoglycemic agent; xenobiotic
antimycin a [no description available]	2.6	1	0	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	12.98	89	3	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
5,5'-dimethyl-2,2'-bipyridyl 5,5'-dimethyl-2,2'-bipyridyl: structure in first source	2.6	1	0	bipyridines
dichlorobenzyl alcohol 2,4-dichlorobenzyl alcohol : A member of the class of benzyl alcohols that is benzyl alcohol in which the hydrogens at positions 2 and 4 are replaced by chlorines.	2.6	1	0	benzyl alcohols; dichlorobenzene	antiseptic drug
phenethyl isothiocyanate phenethyl isothiocyanate: a dietary liver aldehyde dehydrogenase inhibitor; promotes urinary bladder carcinoma. phenethyl isothiocyanate : An isothiocyanate having a phenethyl group attached to the nitrogen. It is a naturally occurring compound found in some cruciferous vegetables (e.g. watercress) and is known to possess anticancer properties.	2.31	1	0	isothiocyanate	antineoplastic agent; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; metabolite
1,2-benzisothiazoline-3-one 1,2-benzisothiazoline-3-one: a preservative in water-based solutions such as paints, cutting fluids, printing inks, cleaning agents, polyvinyl chloride gloves, etc.. benzo[d]isothiazol-3-one : An organic heterobicyclic compound based on a fused 1,2-thiazole and benzene bicyclic ring skeleton, with the S atom positioned adjacent to one of the positions of ring fusion.	2.31	1	0	organic heterobicyclic compound; organonitrogen heterocyclic compound	disinfectant; drug allergen; environmental contaminant; platelet aggregation inhibitor; sensitiser; xenobiotic
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	2.6	1	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
streptomycin [no description available]	2.43	2	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
dideoxyadenosine Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.	2.6	1	0	adenosines; purine 2',3'-dideoxyribonucleoside	EC 3.5.4.4 (adenosine deaminase) inhibitor; EC 4.6.1.1 (adenylate cyclase) inhibitor
floxacillin Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.	2.41	1	0	penicillin allergen; penicillin	antibacterial drug
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	2.6	1	0	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
3-deazaadenosine 3-deazaadenosine: RN given refers to parent cpd.	2.6	1	0
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.6	1	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
fluorine Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.	2.76	3	0	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
ancitabine Ancitabine: Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.. ancitabine : An organic heterotricyclic compound resulting from the formal condensation of the oxo group of cytidine to the 2' position with loss of water to give the corresponding cyclic ether. A prodrug, it is metabolised to the antineoplastic agent cytarabine, so is used to maintain a more constant antineoplastic action.	2.6	1	0	diol; organic heterotricyclic compound	antimetabolite; antineoplastic agent; prodrug
chloropyramine chloropyramine: RN given refers to parent cpd; structure	2.6	1	0	aminopyridine
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.6	1	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
n'-nitrosonornicotine N'-nitrosonornicotine: structure; a potent carcinogen in laboratory animals	2.6	1	0	pyridines; pyrrolidines
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	2.6	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	2.13	1	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.05	1	0	penicillin allergen; penicillin	antibacterial drug
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.6	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
ribavirin Rebetron: Rebetron is tradename	2.53	2	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
pyridoxal phosphate [no description available]	2.6	1	0	pyridinecarbaldehyde
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	3.64	2	0	benzamides; carboxylic ester
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	2.6	1	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
oltipraz oltipraz : A 1,2-dithiole that is 3H-1,2-dithiole-3-thione substituted at positions 4 and 5 by methyl and pyrazin-2-yl groups respectively.	2.6	1	0	1,2-dithiole; pyrazines	angiogenesis modulating agent; antimutagen; antineoplastic agent; antioxidant; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; neurotoxin; protective agent; schistosomicide drug
fiacitabine fiacitabine: anti-herpes virus agent which also inhibits growth of certain human tumor cell lines in vitro.	2.6	1	0
ranolazine Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.	2.6	1	0	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol
brequinar brequinar : A quinolinemonocarboxylic acid that is quinoline substituted by 2'-fluoro[1,1'-biphenyl]-4-yl, methyl, carboxy and fluoro groups at positions 2, 3, 4, and 6, respectively. It is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis. The compound exhibits antineoplastic and antiviral properties.	2.6	1	0	biphenyls; monocarboxylic acid; monofluorobenzenes; quinolinemonocarboxylic acid	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral agent; EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor; immunosuppressive agent; pyrimidine synthesis inhibitor
imiquimod Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.	2.6	1	0	imidazoquinoline	antineoplastic agent; interferon inducer
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	2.6	1	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	2.6	1	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
celgosivir celgosivir: inhibits glycoprotein processing & the growth of HIVs	2.6	1	0
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.6	1	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
lamivudine [no description available]	2.6	1	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	2.6	1	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
zanamivir Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.	2.6	1	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
adefovir dipivoxil bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.	2.6	1	0	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug
emtricitabine Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.	2.6	1	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
octyl gallate [no description available]	2.6	1	0	gallate ester	food antioxidant; hypoglycemic agent; plant metabolite
zinc ethylphenyldithiocarbamate [no description available]	2.31	1	0
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	2.41	2	0
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.6	1	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	2.6	1	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.11	1	0	D-glucopyranose	epitope; mouse metabolite
betulinic acid [no description available]	2.6	1	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
arctigenin arctigenin: precursor to catechols; in many plants	2.6	1	0	lignan
baicalin [no description available]	2.82	2	0	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	2.6	1	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
amprenavir [no description available]	2.6	1	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	2.53	2	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.6	1	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
1,2-dipalmitoylphosphatidylglycerol dipalmitoyl phosphatidylglycerol : A phosphatidylglycerol in which the phosphatidyl acyl groups are both palmitoyl.	2.05	1	0	phosphatidylglycerol
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose pentagalloylglucose: pentahydroxy gallic acid ester of glucose; a phytogenic antineoplastic agent and antibacterial agent. 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose : A galloyl-beta-D-glucose compound having five galloyl groups in the 1-, 2-, 3-, 4- and 6-positions.	2.82	2	0	gallate ester; galloyl beta-D-glucose	anti-inflammatory agent; antineoplastic agent; geroprotector; hepatoprotective agent; plant metabolite; radiation protective agent; radical scavenger
cephalotaxine [no description available]	2.6	1	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; cyclic acetal; enol ether; organic heteropentacyclic compound; secondary alcohol; tertiary amino compound
desipramine hydrochloride desipramine hydrochloride : The hydrochloride salt of desipramine.	2.6	1	0	hydrochloride	drug allergen
mefloquine hydrochloride [no description available]	2.6	1	0	hydrochloride
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	6.56	11	0	cephalosporin	fungal metabolite
aloxistatin aloxistatin: a membrane-permeable cysteine protease inhibitor. aloxistatin : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide.	2.6	1	0	epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide	anticoronaviral agent; cathepsin B inhibitor
propazole propazole: RN given refers to parent cpd; structure	2.6	1	0	benzimidazoles
fropenem [no description available]	2.05	1	0	faropenem
prulifloxacin prulifloxacin: structure given in first source	2.6	1	0	fluoroquinolone antibiotic; quinolone antibiotic
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	2.6	1	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
bergenin bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure	2.6	1	0	trihydroxybenzoic acid	metabolite
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	3.19	1	0	1,2,3-triazole
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	2.6	1	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.6	1	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
brinzolamide brinzolamide: an antiglaucoma agent	2.6	1	0	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor
dipropylacetamide dipropylacetamide: structure. valpromide : A fatty amide derived from valproic acid.	2.6	1	0	fatty amide	geroprotector; metabolite; teratogenic agent
oxprenolol hydrochloride [no description available]	2.6	1	0
opipramol hydrochloride [no description available]	2.6	1	0
moroxydine [no description available]	2.6	1	0	biguanides
thioxolone tioxolone : A 1,3-benzoxathiole having a hydroxy substituent at the 6-position.	2.6	1	0	benzoxathiole	antiseborrheic
vanitiolide [no description available]	2.31	1	0	methoxybenzenes; phenols
honokiol [no description available]	2.6	1	0	biphenyls
nobiletin nobiletin : A methoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 8, 3' and 4' respectively.	2.6	1	0	methoxyflavone	antineoplastic agent; plant metabolite
lycorine lycorine: from bulbs of LYCORIS & other plants; RN given refers to (1 alpha,2 beta)-isomer; structure in Merck Index, 9th ed, #5444. lycorine : An indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it has been shown to exhibit antimalarial activity.	2.6	1	0	indolizidine alkaloid	anticoronaviral agent; antimalarial; plant metabolite; protein synthesis inhibitor
leupeptin [no description available]	2.6	1	0	aldehyde; tripeptide	bacterial metabolite; calpain inhibitor; cathepsin B inhibitor; EC 3.4.21.4 (trypsin) inhibitor; serine protease inhibitor
tetrandrine tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity	2.6	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
LSM-4272 [no description available]	2.31	1	0	beta-carbolines
doripenem Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.	3.14	1	0	carbapenems
calpeptin [no description available]	2.6	1	0	amino acid amide
fangchinoline [no description available]	2.6	1	0	aromatic ether; bisbenzylisoquinoline alkaloid; macrocycle	anti-HIV-1 agent; anti-inflammatory agent; antineoplastic agent; antioxidant; neuroprotective agent; plant metabolite
maslinic acid (2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria	2.6	1	0	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	6.14	10	0	carbamate ester; oxazolidinone	metabolite
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	2.6	1	0	hydroxy-1,2-naphthoquinone
loganin [no description available]	2.6	1	0	beta-D-glucoside; cyclopentapyran; enoate ester; iridoid monoterpenoid; methyl ester; monosaccharide derivative; secondary alcohol	anti-inflammatory agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.4.23.46 (memapsin 2) inhibitor; neuroprotective agent; plant metabolite
moexipril [no description available]	2.6	1	0	peptide
aucubin [no description available]	2.6	1	0	organic molecular entity	metabolite
catalpol [no description available]	2.6	1	0	organic molecular entity	metabolite
lekoptin (S)-verapamil : A 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile that has S configuration.	2.6	1	0	2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
lopinavir [no description available]	2.31	1	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	5.87	12	0
zpck ZPCK: alkylates histidine residue at active center of bovine chymotrypsin	2.31	1	0
tingenone tingenone: quinonoid triterpene isolated from Euonymus tingens	2.31	1	0
n-methyladenosine N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.	2.6	1	0	methyladenosine
sivelestat sivelestat: inhibitor of neutrophil elastase; structure given in first source	2.6	1	0	N-acylglycine; pivalate ester
pyronaridine [no description available]	2.6	1	0	aminoquinoline
geniposide [no description available]	2.6	1	0	terpene glycoside
daidzin daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).	2.6	1	0	7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative	plant metabolite
tanshinone tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent	2.31	1	0	abietane diterpenoid	anticoronaviral agent
sophocarpine [no description available]	2.6	1	0
marimastat marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary. marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.	2.6	1	0	hydroxamic acid; secondary carboxamide	antineoplastic agent; matrix metalloproteinase inhibitor
elacridar Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source	2.6	1	0
celastrol [no description available]	2.82	2	0	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer)	2.6	1	0	leucine derivative
vadimezan vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.	2.6	1	0	monocarboxylic acid; xanthones	antineoplastic agent
e 64 E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-)	2.6	1	0	dicarboxylic acid monoamide; epoxy monocarboxylic acid; guanidines; L-leucine derivative; zwitterion	antimalarial; antiparasitic agent; protease inhibitor
sulbactam [no description available]	2	1	0	penicillanic acids
umifenovir umifenovir: an antiviral agent	2.6	1	0	indolyl carboxylic acid
safinamide safinamide: short-acting inhibitor of MOA-B; FCE 26743 is (S)-isomer, FCE 28073 is (R)-isomer; structure in first source	2.6	1	0	amino acid amide
ilomastat CS 610: matrix metalloproteinase inhibitor; structure in first source. ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor	2.6	1	0	hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid	anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent
carbapenems [no description available]	4.09	2	0
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	2.78	3	0	beta-lactam antibiotic allergen; beta-lactam
atazanavir atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).	2.6	1	0	carbohydrazide	antiviral drug; HIV protease inhibitor
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	2.05	1	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ertapenem Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.	2.13	1	0	carbapenemcarboxylic acid; pyrrolidinecarboxamide	antibacterial drug
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	9.54	5	1	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
vx 497 N-3-(3-(3-methoxy-4-oxazol-5-ylphenyl)ureido)benzylcarbamic acid tetrahydrofuran-3-yl ester: structure in first source	2.6	1	0
bcx 1812 [no description available]	2.6	1	0	3-hydroxy monocarboxylic acid; acetamides; cyclopentanols; guanidines	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	2.6	1	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
olmesartan olmesartan: an active metabolite of CS 866	2.6	1	0	biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent
telbivudine [no description available]	2.6	1	0	pyrimidine 2'-deoxyribonucleoside	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
celastrol methyl ester celastrol methyl ester: isolated from Tripterygium wilfordii; potent inhibitory activity on both Kir2.1 and ERG1 potassium channels, leading to LONG QT SYNDROME	2.82	2	0	carboxylic ester
resiquimod S 28463: structure given in first source	2.6	1	0	imidazoquinoline
miltirone miltirone: from Salvis miltiorrhiza Bunge; central benzodiazepine receptor ligand; structure given in first source	2.31	1	0	abietane diterpenoid
cryptotanshinone cryptotanshinone: from Salvia miltiorrhiza	2.31	1	0	abietane diterpenoid	anticoronaviral agent
tanshinone ii a tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source	2.82	2	0	abietane diterpenoid
2-phenyl-1,2-benzisothiazol-3-(2h)-one 2-phenyl-1,2-benzisothiazol-3-(2H)-one: structure given in first source; sulfur analog of ebselen	2.31	1	0
anacardic acid anacardic acid: isolated from Anacardium occidentale; monophenol monooxygenase inhibitor. anacardic acid : A hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities.	2.6	1	0	hydroxy monocarboxylic acid; hydroxybenzoic acid	anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite
migalastat migalastat: a potent inhibitor of glycolipid biosynthesis	2.6	1	0	piperidines
erlotinib [no description available]	2.6	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
limonin [no description available]	2.6	1	0	epoxide; furans; hexacyclic triterpenoid; lactone; limonoid; organic heterohexacyclic compound	inhibitor; metabolite; volatile oil component
scutellarin scutellarin: see scutellarein for aglycone. scutellarin : The glycosyloxyflavone which is the 7-O-glucuronide of scutellarein.	2.6	1	0	glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antineoplastic agent; proteasome inhibitor
carboxyebselen carboxyebselen: a nitric oxide synthase inhibitor	2.31	1	0
etravirine [no description available]	2.6	1	0	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor
chelidonine chelidonine: benzophenanthridine derived from scoulerine from Chelidonium majus; RN given refers to parent cpd (chelidonine, (5bR-(5balpha,6beta,12alpha))-isomer)	2.6	1	0	alkaloid antibiotic; alkaloid fundamental parent; benzophenanthridine alkaloid
4-n-butylresorcinol 4-n-butylresorcinol: structure in first source	2.6	1	0	resorcinols
darunavir Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.	2.82	2	0	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
iclaprim iclaprim: has antiviral activity. iclaprim : A racemate consisting of equimolar amounts of (R)- and (S)-iclaprim. Both enantiomers exhibit similar, potent bactericidal activity against major Gram-positive pathogens, notably methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA, respectively).. 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine : An aminopyrimidine that is 5-methylpyrimidine-2,4-diamine in which one of the hydrogens of the methyl group has been replaced by a 2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl group.	4.57	4	0	aminopyrimidine; chromenes; cyclopropanes
dapivirine Dapivirine: effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission	2.6	1	0
1-methylpropyl-2-imidazolyl disulfide 1-methylpropyl-2-imidazolyl disulfide: a thioredoxin inhibitor with antineoplastic activity	2.31	1	0	imidazoles
nsc 74859 NSC 74859: inhibits Stat3 binding activity; structure in first source. S3I-201 : An amidobenzoic acid obtained by formal condensation of the carboxy group of [(4-methylbenzene-1-sulfonyl)oxy]acetic acid with the amino group of 4-amino-2-hydroxybenzoic acid.	2.6	1	0	amidobenzoic acid; monohydroxybenzoic acid; tosylate ester	STAT3 inhibitor
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.11	1	0
nsc 95397 [no description available]	2.31	1	0	1,4-naphthoquinones
berbamine [no description available]	2.6	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
u-104 SLC-0111: a carbonic anhydrase inhibitor; structure in first source	2.6	1	0
7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one [no description available]	2.6	1	0	glycoside
nsc 663284 NSC 663284: structure in first source	2.31	1	0	quinolone
bortezomib [no description available]	2.6	1	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.6	1	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
tizoxanide tizoxanide: major metabolite of nitazoxanide; structure in first source	2.6	1	0	salicylamides
arbutin hydroquinone O-beta-D-glucopyranoside : A monosaccharide derivative that is hydroquinone attached to a beta-D-glucopyranosyl residue at position 4 via a glycosidic linkage.	2.6	1	0	beta-D-glucoside; monosaccharide derivative	Escherichia coli metabolite; plant metabolite
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	2.6	1	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
conessine conessine : A steroid alkaloid that is con-5-enine substituted by a N,N-dimethylamino group at position 3. It has been isolated from the plant species of the family Apocynaceae.	2.6	1	0	steroid alkaloid; tertiary amino compound	antibacterial agent; antimalarial; H3-receptor antagonist; plant metabolite
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	2.6	1	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
abacavir abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.	2.82	2	0	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor
linezolid [no description available]	6.98	20	0	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
ferruginol ferruginol: structure in first source. ferruginol : An abietane diterpenoid that is abieta-8,11,13-triene substituted by a hydroxy group at positions 12.	2.31	1	0	abietane diterpenoid; carbotricyclic compound; meroterpenoid; phenols	antibacterial agent; antineoplastic agent; plant metabolite; protective agent
isopimaric acid isopimaric acid: isolated from the bark of Illicium jadifengpi	2.31	1	0	carbotricyclic compound; diterpenoid; monocarboxylic acid
cephaelin cephaelin: do not confuse with cephalin of brain; after emetine this is the most important alkaloid of ipecac; protein synthesis inhibitor. cephaeline : A pyridoisoquinoline comprising emetam having a hydroxy group at the 6'-position and methoxy substituents at the 7'-, 10- and 11-positions.	2.6	1	0	pyridoisoquinoline
(-)-usnic acid (-)-usnic acid : The (-)-enantiomer of usnic acid.	2.6	1	0	usnic acid	EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
acetylleucyl-leucyl-norleucinal acetylleucyl-leucyl-norleucinal: a proteasome inhibitor. acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.	2.82	2	0	aldehyde; tripeptide	cysteine protease inhibitor
sultamicillin sultamicillin: contains ampicillin & sulbactam	2	1	0	penicillanic acid ester
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.6	1	0	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	2.6	1	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	7.96	4	0
lycopene [no description available]	2.6	1	0	acyclic carotene	antioxidant; plant metabolite
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	2.78	3	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
gw 3965 GW 3965: a liver X receptor ligand	2.31	1	0	diarylmethane
roflumilast [no description available]	2.6	1	0	aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound	anti-asthmatic drug; phosphodiesterase IV inhibitor
L-cycloserine L-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has S configuration. An antibiotic isolated from Erwinia uredovora.	2.6	1	0	4-amino-1,2-oxazolidin-3-one	anti-HIV agent; anticonvulsant; EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	2.6	1	0	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
bevirimat bevirimat: an HIV inhibitor; disrupts late step in processing HIV Major Core Protein p24, preventing the capsid precursor p25 from being converted to mature capsid p24. bevirimat : A pentacyclic triterpenoid obtained by the formal condensation of 2,2-dimethylsuccinic acid with the 3-hydroxy group of betulinic acid. It is isolated from the Chinese herb Syzygium claviflorum. The first in the class of HIV-1 maturation inhibitors to be studied in humans, bevirimat was identified as a potent HIV drug candidate and several clinical trials were conducted, but development into a new drug was plagued by numerous resistance-related problems.	2.6	1	0	dicarboxylic acid monoester; monocarboxylic acid; pentacyclic triterpenoid	HIV-1 maturation inhibitor; metabolite
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.82	2	0	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	2.82	2	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
posaconazole [no description available]	2.6	1	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
gw 257406x maribavir: has antiviral activity against human cytomegalovirus	2.6	1	0
shikonin shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities	2.6	1	0	hydroxy-1,4-naphthoquinone
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide [no description available]	2.6	1	0	tropane alkaloid
cmx 001 [no description available]	2.6	1	0
amd 8664 [no description available]	2.6	1	0
bay 41-4109 BAY 41-4109: structure in first source	2.6	1	0
bay 57-1293 pritelivir: herpes simplex virus 1 helicase-primase inhibitor	2.6	1	0
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	2.6	1	0
isoxanthohumol isoxanthohumol: structure in first source	2.6	1	0	flavanones
1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide [no description available]	2.31	1	0	indolecarboxamide	anticoronaviral agent
4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide: a c-FLIP inhibitor; structure in first source	2.6	1	0	aromatic ether
mecarbinate [no description available]	2.6	1	0
pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.	2.11	1	0	diphosphate ion
acetyl-aspartyl-glutamyl-valyl-aspartal acetyl-aspartyl-glutamyl-valyl-aspartal: a capase inhibitor. Ac-Asp-Glu-Val-Asp-H : A tetrapeptide consisting of two L-aspartic acid residues, an L-glutamyl residue and an L-valine residue with an acetyl group at the N-terminal and with the C-terminal carboxy group reduced to an aldehyde. It is an inhibitor of caspase-3/7.	2.6	1	0	tetrapeptide	protease inhibitor
octotropine methylbromide octotropine methylbromide: minor descriptor (65-86); on line & INDEX MEDICUS search TROPANES (69-86); RN given refers to endo-isomer. anisotropine methylbromide : A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide.	2.6	1	0
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	2.6	1	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
jrf 12 N2,N4-dibenzylquinazoline-2,4-diamine: a selective, potent, reversible, and ATP-competitive p97 inhibitor	2.6	1	0
3,4'-dihydroxyflavone 3,4'-dihydroxyflavone: an antioxidant; structure in first source	2.6	1	0
1-(4-Methoxyphenyl)-2-nitroethylene 4-methoxy-beta-nitrostyrene: has vasodilator activity; structure in first source	2.31	1	0	methoxybenzenes
3-(3,4-dimethoxyphenyl)propenoic acid 3-(3,4-dimethoxyphenyl)propenoic acid: structure given in first source; RN given refers to parent cpd. 3,4-dimethoxycinnamic acid : A methoxycinnamic acid that is trans-cinnamic acid substituted by methoxy groups at positions 3' and 4' respectively.	2.6	1	0	methoxycinnamic acid
isoferulic acid isoferulic acid: isomer of ferulic acid; structure. isoferulic acid : A ferulic acid consisting of trans-cinnamic acid bearing methoxy and hydroxy substituents at positions 4 and 3 respectively on the phenyl ring.	2.6	1	0	ferulic acids	antioxidant; biomarker; metabolite
cyclouridine cyclouridine: structure given in third source	2.6	1	0
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.82	2	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
zucapsaicin [no description available]	2.6	1	0	methoxybenzenes; phenols
nbd 556 [no description available]	2.6	1	0
chlorogenic acid caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.	2.31	1	0	cinnamate ester; tannin	food component; plant metabolite
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	2.6	1	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
4,5,6,7-tetrachloroindan-1,3-dione 4,5,6,7-tetrachloroindan-1,3-dione: inhibits ubiquitin C-terminal hydrolase L1	2.6	1	0
srpin340 SRPIN340: Serine-Arginine-Rich Protein Kinase Inhibitor	2.6	1	0
pr-619 [no description available]	2.6	1	0
5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine [no description available]	2.31	1	0	sulfonic acid derivative	anticoronaviral agent
p5091 P5091: inhibits ubiquitin-specific protease 7; structure in first source	2.6	1	0
S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate [no description available]	2.31	1	0	acetylenic compound; furans; organofluorine compound; thioester; triazoles
fusidic acid Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.	2.05	1	0	11alpha-hydroxy steroid; 3alpha-hydroxy steroid; alpha,beta-unsaturated monocarboxylic acid; steroid acid; steroid antibiotic; sterol ester	EC 2.7.1.33 (pantothenate kinase) inhibitor; Escherichia coli metabolite; protein synthesis inhibitor
trovirdine trovirdine: HIV-1 reverse transcriptase inhibitor	2.6	1	0
hmr 3647 [no description available]	2.05	1	0
fti 277 [no description available]	2.6	1	0
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.6	1	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
vicriviroc vicriviroc: structure in first source	2.6	1	0	(trifluoromethyl)benzenes
telaprevir [no description available]	2.82	2	0	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	2.6	1	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.6	1	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
telavancin telavancin: an anti-infective agent; structure in first source. telavancin : A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria.	7.69	21	0	glycopeptide	antibacterial drug; antimicrobial agent
yya-021 YYA-021: an HIV entry inhibitor; structure in first source	2.6	1	0
N-(4-Butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-pyridin-3-ylethyl]furan-2-carboxamide [no description available]	2.31	1	0	aromatic amide; furans	anticoronaviral agent
8-(Trifluoromethyl)-9H-purin-6-amine [no description available]	2.31	1	0	6-aminopurines	anticoronaviral agent
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	2.31	1	0	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
suramin sodium suramin(6-) : An organosulfate oxoanion that is the hexanion of suramin resulting from the deprotonation of the six sulfo groups; major species at pH 7.3.	2.31	1	0	organosulfate oxoanion
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione: a GSK3beta inhibitor. TDZD-8 : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease.	2.31	1	0	benzenes; thiadiazolidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sb 415286 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source	2.6	1	0	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	2.82	2	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
ginkgetin ginkgetin: from Cephalotaxus drupacea; biflavone; active against HSV-1; structure given in first source. ginkgetin : A biflavonoid that is the 7,4'-dimethyl ether derivative of amentoflavone. Isolated from Ginkgo biloba and Dioon, it exhibits anti-HSV-1, antineoplastic and inhibitory activities towards arachidonate 5-lipoxygenase and cyclooxygenase 2.	2.31	1	0	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	anti-HSV-1 agent; antineoplastic agent; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; metabolite
tak-220 TAK-220: structure in first source	2.6	1	0
jtk-303 [no description available]	2.6	1	0	aromatic ether; monochlorobenzenes; organofluorine compound; quinolinemonocarboxylic acid; quinolone	HIV-1 integrase inhibitor
nbd 557 [no description available]	2.6	1	0
quercetin [no description available]	2.31	1	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.31	1	0	trihydroxyflavone	antineoplastic agent; metabolite
luteolin [no description available]	2.31	1	0	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
5'-o-caffeoylquinic acid trans-5-O-caffeoyl-D-quinic acid : A cinnamate ester obtained by formal condensation of the carboxy group of trans-caffeic acid with the 5-hydroxy group of quinic acid.	2.6	1	0	cinnamate ester; cyclitol carboxylic acid	plant metabolite
luteolin-7-glucoside luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.6	1	0	beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antioxidant; plant metabolite
cyclosporine [no description available]	2.6	1	0
harmine Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.	2.6	1	0	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
eprosartan eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.	2.6	1	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	2.6	1	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
entacapone entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.	2.6	1	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
amentoflavone [no description available]	2.82	2	0	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite
baicalein [no description available]	2.82	2	0	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
genkwanin genkwanin: structure. genkwanin : A monomethoxyflavone that is apigenin in which the hydroxy group at position 7 is methylated.	2.6	1	0	dihydroxyflavone; monomethoxyflavone	metabolite
hyperoside quercetin 3-O-beta-D-galactopyranoside : A quercetin O-glycoside that is quercetin with a beta-D-galactosyl residue attached at position 3. Isolated from Artemisia capillaris, it exhibits hepatoprotective activity.	2.6	1	0	beta-D-galactoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	hepatoprotective agent; plant metabolite
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	2.6	1	0	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
3-methylquercetin isorhamnetin : A monomethoxyflavone that is quercetin in which the hydroxy group at position 3' is replaced by a methoxy group.	2.6	1	0	7-hydroxyflavonol; monomethoxyflavone; tetrahydroxyflavone	anticoagulant; EC 1.14.18.1 (tyrosinase) inhibitor; metabolite
kaempferide kaempferide: structure in first source. kaempferide : A monomethoxyflavone that is the 4'-O-methyl derivative of kaempferol.	2.6	1	0	7-hydroxyflavonol; monomethoxyflavone; trihydroxyflavone	antihypertensive agent; metabolite
orientin orientin: structure given in first source; RN given refers to the (D-glucopyranosyl)-isomer. orientin : A C-glycosyl compound that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 8.	2.6	1	0	3'-hydroxyflavonoid; C-glycosyl compound; tetrahydroxyflavone	antioxidant; metabolite
sciadopitysin sciadopitysin: biflavonoid from Taxus celebica & Ginkgo biloba. sciadopitysin : A biflavonoid that is a 7, 4', 4'''-trimethyl ether derivative of amentoflavone.	2.31	1	0	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	bone density conservation agent; platelet aggregation inhibitor
scutellarein scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.	2.82	2	0	tetrahydroxyflavone	metabolite
trans-2,3',4,5'-tetrahydroxystilbene trans-2,3',4,5'-tetrahydroxystilbene: hydroxystilbene oxyresveratrol	2.6	1	0	stilbenoid
polydatin trans-piceid : A stilbenoid that is trans-resveratrol substituted at position 3 by a beta-D-glucosyl residue.	2.6	1	0	beta-D-glucoside; monosaccharide derivative; polyphenol; stilbenoid	anti-arrhythmia drug; antioxidant; geroprotector; hepatoprotective agent; metabolite; nephroprotective agent; potassium channel modulator
chicoric acid chicoric acid: inhibits HIV-1 integrase	2.6	1	0	organooxygen compound	geroprotector; HIV-1 integrase inhibitor
acteoside acteoside: a protein kinase C inhibitor with hepatoprotective, anti-asthmatic, and analgesic activities; a phenylethanoid glycoside related to isoacteoside; from leaves of Lippia multiflora (Verbenaceae). acteoside : A glycoside that is the alpha-L-rhamnosyl-(1->3)-beta-D-glucoside of hydroxytyrosol in which the hydroxy group at position 4 of the glucopyranosyl moiety has undergone esterification by formal condensation with trans-caffeic acid.	2.6	1	0	catechols; cinnamate ester; disaccharide derivative; glycoside; polyphenol	anti-inflammatory agent; antibacterial agent; antileishmanial agent; neuroprotective agent; plant metabolite
1-palmitoyl-2-oleoylphosphatidylethanolamine 1-palmitoyl-2-oleoylphosphatidylethanolamine: RN given refers to (Z)-isomer; RN for cpd without isomeric designation not available 12/88. 1-palmitoyl-2-oleoyl phosphatidylethanolamine : A phosphatidylethanolamine in which the phosphatidyl acyl groups at C-1 and C-2 are palmitoyl and oleoyl respectively.	2.46	2	0	(18R,21S)-24-amino-21-hydroxy-21-oxido-15-oxo-16,20,22-trioxa-21lambdalambda(5)-phosphatetracosan-18-yl icosanoate; phosphatidylethanolamine
1-palmitoyl-2-oleoylglycero-3-phosphoglycerol [no description available]	2.05	1	0	phosphatidylglycerol
dorzolamide dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.	2.6	1	0	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	2.6	1	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
benzyloxycarbonyl-phe-ala-fluormethylketone cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).	2.82	2	0
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester DAPT : A dipeptide consisting of alanylphenylglycine derivatised as a 3,5-difluorophenylacetamide at the amino terminal and a tert-butyl ester at the carboxy terminal. A gamma-secretase inhibitor.	2.6	1	0	carboxylic ester; difluorobenzene; dipeptide; tert-butyl ester	EC 3.4.23.46 (memapsin 2) inhibitor
casticin casticin: from fruit of Vitex rotundifolia; structure in second source. casticin : A tetramethoxyflavone that consists of quercetagetin in which the hydroxy groups at positions 3, 6, 7 and 4' have been replaced by methoxy groups. It has been isolated from Eremophila mitchellii.	2.6	1	0	dihydroxyflavone; tetramethoxyflavone	apoptosis inducer; plant metabolite
bilobetin bilobetin: a phospholipase A2 antagonist	2.31	1	0	flavonoid oligomer
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one: isolated from the Chinese herb Scutellariae radix. oroxylin A : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-6.	2.6	1	0	dihydroxyflavone; monomethoxyflavone	antineoplastic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside: Tyrosinase inhibitor from Polygonum multiflorum; structure in first source. (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside : A stilbenoid that is trans-stilbene which has been substituted by hydroxy groups at positions 2, 3, 5, and 4', and in which the hydroxy group at positon 2 has then been converted to the corresponding the beta-D-glucoside.	2.6	1	0	beta-D-glucoside; resorcinols; stilbenoid	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; cyclooxygenase 2 inhibitor; platelet aggregation inhibitor
tyrphostin ag 555 [no description available]	2.6	1	0
pd 151746 [no description available]	2.6	1	0
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	2.6	1	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
verteporfin (2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid : The 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid.	2.6	1	0
batimastat batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor. batimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor.	2.6	1	0	hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	2.82	2	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
diphenylhexatriene Diphenylhexatriene: A fluorescent compound that emits light only in specific configurations in certain lipid media. It is used as a tool in the study of membrane lipids.	2.05	1	0	alkatriene	fluorochrome
cinanserin Cinanserin: A serotonin antagonist with limited antihistaminic, anticholinergic, and immunosuppressive activity.. cinanserin : An aryl sulfide that is (2E)-3-phenyl-N-(2-sulfanylphenyl)prop-2-enamide in which the hydrogen of the thiol group is substituted by a 3-(dimethylamino)propyl group. It is a 5-hydroxytryptamine receptor antagonist and an inhibitor of SARS-CoV replication.	2.31	1	0	aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
solanesol solanesol : A nonaprenol that is hexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-ol substituted by 9 methyl groups at positions 3, 7, 11, 15, 19, 23, 27, 31 and 35 (the all-trans0stereoisomer).	2.6	1	0	nonaprenol; primary alcohol	plant metabolite
pepstatin pepstatin: inhibits the aspartic protease endothiapepsin	2.6	1	0	pentapeptide; secondary carboxamide	bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor
ceftriaxone [no description available]	2.46	2	0	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
l 685458 L 685458: a gamma-secretase inhibitor; structure in first source. L-685,458 : A peptide and carboxamide that is L-leucyl-L-phenylalaninamide, L-Leu-L-Phe-NH2, which has been acylated on the N-terminus by a Phe-Phe hydroxyethylene dipeptide isotere, 2R-benzyl-5S-tert-butoxycarbonylamino-4R-hydroxy-6-phenylhexanoic acid. Compounds based on the structure of L-685,458 are potent inhibitors of gamma-secretase, which mediates the final catalytic step that generates the amyloid beta-peptide (Abeta), which assembles into the neurotoxic aggregates in the brains of sufferers of Alzheimer's disease.	2.6	1	0	carbamate ester; monocarboxylic acid amide; peptide; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor; peptidomimetic
bms 806 BMS 806: prevents entry of HIV into cells by binding HIV envelope protein gp120; no further info available 4/2002	2.6	1	0
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone [no description available]	2.6	1	0
tulobuterol hydrochloride [no description available]	2.6	1	0	organic molecular entity
salubrinal salubrinal: prevents dephosphorylation of eIF2alpha; structure in first source. salubrinal : A member of the class of quinolines that is a mixed aminal resulting from the formal condensation oftrichloroacetaldehyde with the amide nitrogen of trans-cinnamamide and the primary amino group of 1-quinolin-8-ylthiourea. It is a selective inhibitor of cellular complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit alpha (eIF2alpha).	2.6	1	0	aminal; organochlorine compound; quinolines; secondary carboxamide; thioureas
cci 15641 [no description available]	2.05	1	0	cephalosporin
N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide : A tripeptide resulting from the formal condensation of the carboxy group of N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valine with the amino group of benzyl (2E,4S)-4-(L-leucylamino)-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate. It is an inhibitor of the main protease of SARS-CoV-2.	2.31	1	0	benzyl ester; isoxazoles; pyrrolidin-2-ones; tripeptide	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
germacrone germacrone: isolated from Curcuma wenyujin	2.6	1	0	germacrane sesquiterpenoid; olefinic compound	androgen antagonist; anti-inflammatory agent; antifeedant; antifungal agent; antimicrobial agent; antineoplastic agent; antioxidant; antitussive; antiviral agent; apoptosis inducer; autophagy inducer; hepatoprotective agent; insecticide; neuroprotective agent; plant metabolite; volatile oil component
(2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid: an acyclic retinoid that suppresses hepatocellular carcinoma recurrence; structure in first source	2.6	1	0
lithospermic acid [no description available]	2.6	1	0
laq824 LAQ824: Histone deacetylase inhibitor	2.6	1	0
ekb 569 EKB 569: an EGF receptor kinase inhibitor	2.6	1	0	aminoquinoline; monocarboxylic acid amide; monochlorobenzenes; nitrile	protein kinase inhibitor
rilpivirine [no description available]	2.6	1	0	aminopyrimidine; nitrile	EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor
(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one [no description available]	2.6	1	0	germacranolide
4,5-di-O-caffeoylquinic acid [no description available]	2.6	1	0	quinic acid
indigo carmine 3,5-di-O-(E)-caffeoylquinic acid: from roots of Lychnophora ericoides; structure in first source. 3,5-di-O-caffeoyl quinic acid : A carboxylic ester that is the diester obtained by the condensation of the hydroxy groups at positions 3 and 5 of (-)-quinic acid with the carboxy group of trans-caffeic acid. Isolated from Brazilian propolis and Suaeda glauca, it exhibits hepatoprotective and cytotoxic activities.	2.6	1	0
Ethyl (E,4S)-4-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-phenylpropanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate [no description available]	2.31	1	0	dipeptide	anticoronaviral agent
mdl 201053 MDL 201053: Immunosuppressive Agent; RN given refers to compound with no isomeric designation	2.31	1	0
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.6	1	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone [no description available]	2.6	1	0	oligopeptide
vildagliptin [no description available]	2.6	1	0	amino acid amide
belinostat [no description available]	2.6	1	0	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
hdac-42 HDAC-42: structure in first source	2.6	1	0	amidobenzoic acid
5-Chloro-3-pyridinyl 2-furoate [no description available]	2.31	1	0	carboxylic ester	anticoronaviral agent
chlorhexidine Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.	2.6	1	0	biguanides; monochlorobenzenes	antibacterial agent; antiinfective agent
gs-7340 tenofovir alafenamide: component of Biktarvy. tenofovir alafenamide : An L-alanine derivative that is isopropyl L-alaninate in which one of the amino hydrogens is replaced by an (S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl group. A prodrug for tenofovir, it is used (as the fumarate salt) in combination therapy for the treatment of HIV-1 infection.	2.6	1	0	6-aminopurines; ether; isopropyl ester; L-alanine derivative; phosphoramidate ester	antiviral drug; HIV-1 reverse transcriptase inhibitor; prodrug
iniparib [no description available]	2.6	1	0	carbonyl compound; organohalogen compound
n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide [no description available]	2.6	1	0
pri-2205 [no description available]	2.6	1	0
mk 0752 [no description available]	2.6	1	0
givinostat [no description available]	2.6	1	0	carbamate ester
pd 144418 [no description available]	2.6	1	0
bicyclol bicyclol: an antihepatitis drug, on the metabolism and hepatotoxicity of aflatoxin B1 (AFB1) in rats.	2.6	1	0
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	2.6	1	0	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
ly 450139 [no description available]	2.6	1	0	peptide
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.6	1	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
rivaroxaban Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.	2.6	1	0	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
sb 3ct compound SB 3CT compound: a matrix metalloproteinase-2 inhibitor; structure in first source	2.6	1	0	aromatic ether
ginsenoside rb1 [no description available]	2.6	1	0	ginsenoside; glycoside; tetracyclic triterpenoid	anti-inflammatory drug; anti-obesity agent; apoptosis inhibitor; neuroprotective agent; plant metabolite; radical scavenger
gentamicin sulfate [no description available]	2.45	2	0
sp 100030 N-(3,5-bis(trifluoromethyl)phenyl)-2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxamide: transcription factor inhibitor specific to T-cells	2.31	1	0
rucaparib AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source	2.6	1	0	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
gw0742 GW 610742: structure in first source	2.31	1	0	monocarboxylic acid
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- [no description available]	2.6	1	0	organonitrogen heterocyclic compound; organosulfur heterocyclic compound
cetilistat cetilistat: lipase inhibitor in randomized, placebo-controlled study of weight reduction in obese patients (3/2007)	2.6	1	0	benzoxazine
ym 201636 6-amino-N-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide: an antiviral agent; structure in first source	2.6	1	0	aromatic amide
benzyloxycarbonyl-isoleucyl-glutamyl(o-tert-butyl)-alanyl-leucinal benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal: inhibits chymotrypsin activity of the proteasome	2.31	1	0
fidaxomicin Fidaxomicin: A narrow-spectrum macrolide antibacterial agent that is used in the treatment of diarrhea associated with CLOSTRIDIUM DIFFICILE INFECTION.. fidaxomicin : An 18-membered macrolide that is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. A narrow spectrum antibiotic used for treatment of Clostridium difficile-related infections.	3.15	1	0
vorapaxar vorapaxar: has antiplatelet activity; structure in first source. vorapaxar : A carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethynyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation.	2.11	1	0	carbamate ester; lactone; naphthofuran; organofluorine compound; pyridines	cardiovascular drug; platelet aggregation inhibitor; protease-activated receptor-1 antagonist
linagliptin Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.. linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes.	2.6	1	0	aminopiperidine; quinazolines	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	2.31	1	0	organic cation
azd 6244 AZD 6244: a MEK inhibitor	2.6	1	0	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
odanacatib odanacatib: a selective inhibitor of cathepsin K for the treatment of post-menopausal osteoporosis; structure in first source	2.6	1	0
apilimod [no description available]	2.6	1	0
apixaban [no description available]	2.6	1	0	aromatic ether; lactam; piperidones; pyrazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
tasimelteon tasimelteon : A member of the class of 1-benzofurans that is propionamide in which one of the amide hydrogens is replaced by a [(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl group. A melatonin receptor agonist used for the treatment of non-24-hour sleep-wake disorder.	2.11	1	0	1-benzofurans; cyclopropanes; monocarboxylic acid amide	melatonin receptor agonist
betrixaban betrixaban: a highly potent, selective, and orally efficacious factor Xa inhibitor; structure in first source. betrixaban : A secondary carboxamide obtained by formal condensation of the carboxy group of 4-(N,N-dimethylcarbamimidoyl)benzoic acid with the amino group of 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. A synthetic anticoagulant compound that targets activated factor Xa in the coagulation cascade.	2.6	1	0	benzamides; guanidines; monochloropyridine; monomethoxybenzene; secondary carboxamide	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
edoxaban edoxaban : A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism.	2.6	1	0	chloropyridine; monocarboxylic acid amide; tertiary amino compound; thiazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor; platelet aggregation inhibitor
saracatinib [no description available]	2.6	1	0	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection.	2.82	2	0	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
triptohypol C triptohypol C : A pentacyclic triterpenoid with formula C29H40O4, originally isolated from the root bark of Tripterygium regelii.	2.31	1	0	benzenediols; monocarboxylic acid; pentacyclic triterpenoid	apoptosis inducer; plant metabolite
ly 411575 [no description available]	2.6	1	0	dibenzoazepine; difluorobenzene; lactam; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor
galidesivir [no description available]	2.6	1	0
PB28 PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.	2.6	1	0	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
2-(4-chlorophenyl)-1,2-benzothiazol-3-one [no description available]	2.31	1	0	benzothiazoles
degrasyn degrasyn: a JAK2 kinase inhibitor that induces rapid degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines; structure in first source	2.6	1	0
epoxomicin [no description available]	2.6	1	0	morpholines; tripeptide	proteasome inhibitor
tedizolid DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.	3.19	1	0	carbamate ester; organofluorine compound; oxazolidinone; primary alcohol; pyridines; tetrazoles	antimicrobial agent; drug metabolite; protein synthesis inhibitor
bms 477118 [no description available]	2.6	1	0	adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
pha 680632 PHA 680632: Aurora kinase inhibitor with potent antitumoral activity; structure in first source	2.6	1	0
tmc 353121 [no description available]	2.6	1	0
amd 070 mavorixafor: a derivative of AMD3100; a CXCR4 blocker	2.6	1	0	aminoquinoline
danoprevir [no description available]	2.6	1	0
np 031112 tideglusib: an NSAID and neuroprotective agent. tideglusib : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a naphthalen-1-yl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta) and has neuroprotective effects. Currently under clinical investigation for the treatment of Alzheimer's disease and progressive supranuclear palsy.	2.31	1	0	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
bms-626529 [no description available]	2.6	1	0
bms-663068 fostemsavir: an HIV-1 attachment inhibitor; structure in first source	2.6	1	0
amenamevir ASP2151: a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes; structure in first source	2.6	1	0
vx 765 belnacasan: a NSAID	2.6	1	0	dipeptide
Dihydrotanshinone I dihydrotanshinone I: extracted from Radix Salviae	2.82	2	0	abietane diterpenoid	anticoronaviral agent
alogliptin alogliptin: structure in first source. alogliptin : A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes.	2.6	1	0	nitrile; piperidines; primary amino compound; pyrimidines	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
tedizolid phosphate tedizolid phosphate: a prodrug of DA-7157; structure in first source. tedizolid phosphate : A phosphate monoester resulting from the formal condensation of equimolar amounts of phosphoric acid with the hydroxy group of tedizolid . It is a prodrug of tedizolid, used for the treatment of acute bacterial skin infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.	4.98	6	0	carbamate ester; organofluorine compound; oxazolidinone; phosphate monoester; pyridines; tetrazoles	antimicrobial agent; prodrug; protein synthesis inhibitor
fr 180204 FR 180204: structure in first source	2.6	1	0	pyrazoles; ring assembly
quisinostat [no description available]	2.6	1	0	indoles
carfilzomib [no description available]	2.6	1	0	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
hcv 796 HCV 796: inhibits HCV RdRp; structure in first source	2.6	1	0
mk-0893 [no description available]	2.31	1	0
resminostat resminostat: a histone deacetylase inhibitor; structure in first source	2.6	1	0
zk 756326 2-(2-(4-(3-phenoxybenzyl)piperazin-1-yl)ethoxy)ethanol: a CC chemokine receptor CCR8 agonist; structure in first source	2.6	1	0	aromatic ether
balapiravir balapiravir: a prodrug of R1479; structure in first source	2.6	1	0
trametinib [no description available]	2.6	1	0	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
deoxyarbutin 4-((tetrahydro-2H-pyran-2-yl)oxy)phenol: has antineoplastic activity; structure in first source	2.6	1	0
abexinostat abexinostat: structure in first source	2.6	1	0	benzofurans
silvestrol silvestrol: isolated from the fruit and twig of Aglaia silvestris. silvestrol : An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.	2.6	1	0	dioxanes; ether; methyl ester; organic heterotricyclic compound	antineoplastic agent; metabolite
narlaprevir narlaprevir: an antiviral agent that inhibits hepatitis C virus NS3 protease. narlaprevir : An azabicyclohexane that is (1R,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane substituted by [(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]aminoacyl and N-({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)-3-methyl-L-valyl groups at positions 2S and 3, respectively. It is a hepatitis C virus (HCV) NS3/4A serine protease inhibitor (Ki = 6 nM) that is used for the treatment of chronic hepatitis C.	2.6	1	0	azabicyclohexane; cyclopropanes; pyrrolidinecarboxamide; secondary carboxamide; sulfone; tertiary carboxamide; ureas	anticoronaviral agent; antiviral drug; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; hepatitis C protease inhibitor
empagliflozin [no description available]	2.11	1	0	aromatic ether; C-glycosyl compound; monochlorobenzenes; tetrahydrofuryl ether	hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor
teneligliptin [no description available]	2.6	1	0	amino acid amide
dextrothyroxine [no description available]	2.6	1	0
veliparib [no description available]	2.6	1	0	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
virginiamycin Virginiamycin: A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.. virginiamycin : A mixture of cyclic polypeptide streptogramin antibiotics produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. The two major components are virginiamycin M1 (also known as pristinamycin IIA) and virginiamycin S1. Virginiamycin has been widely used as a growth promotion agent in livestock and has been to have bacteriostatic activity against Gram-positive organisms such as staphylococci and streptococci.	5.2	6	0
pf 03491390 [no description available]	2.6	1	0
alloin [no description available]	2.6	1	0	anthracenes; C-glycosyl compound; cyclic ketone; phenols	laxative; metabolite
mdv 3100 [no description available]	2.6	1	0	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
Benzotriazol-1-yl 1H-indole-5-carboxylate [no description available]	2.31	1	0	indolyl carboxylic acid	anticoronaviral agent
bms-650032 asunaprevir: an NS3 protease inhibitor against hepatitis C virus	2.6	1	0	oligopeptide
rg 7128 2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine: inhibits HCV polymerase; structure in first source	2.6	1	0
tannins gallotannin : A class of hydrolysable tannins obtained by condensation of the carboxy group of gallic acid (and its polymeric derivatives) with the hydroxy groups of a monosaccharide (most commonly glucose).	2.31	1	0	tannin
ly-146032 [no description available]	3.15	5	0	heterodetic cyclic peptide; lipopeptide antibiotic; lipopeptide; macrocycle; macrolide	antibacterial drug; bacterial metabolite; calcium-dependent antibiotics
dalbavancin [no description available]	3.11	1	0	carbohydrate acid derivative; glycopeptide; monosaccharide derivative; semisynthetic derivative	antibacterial drug; antimicrobial agent
glucagon-like peptide 1 Glucagon-Like Peptide 1: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.	2.11	1	0
5-Bromopyridin-3-yl furan-2-carboxylate [no description available]	2.31	1	0	carboxylic ester	anticoronaviral agent
(5-Chloropyridin-3-yl) 1H-indole-5-carboxylate [no description available]	2.31	1	0	indolyl carboxylic acid	anticoronaviral agent
5-Chloropyridin-3-yl 1H-indole-2-carboxylate [no description available]	2.31	1	0	indolyl carboxylic acid	anticoronaviral agent
ristocetin Ristocetin: An antibiotic mixture of two components, A and B, obtained from Nocardia lurida (or the same substance produced by any other means). It is no longer used clinically because of its toxicity. It causes platelet agglutination and blood coagulation and is used to assay those functions in vitro.. ristocetin : A heterodetic cyclic peptide that is produced by species of Amycolatopsis and Nocardia.	2.15	1	0	glycopeptide; heterodetic cyclic peptide; macrocycle; tetrasaccharide derivative	antibacterial drug; antimicrobial agent; bacterial metabolite; platelet-activating factor receptor agonist
phenylmercuric acetate Phenylmercuric Acetate: A phenyl mercury compound used mainly as a fungicide. Has also been used as a herbicide, slimicide, and bacteriocide.	2.31	1	0	arylmercury compound; benzenes
thimerosal Thimerosal: An ethylmercury-sulfidobenzoate that has been used as a preservative in VACCINES; ANTIVENINS; and OINTMENTS. It was formerly used as a topical antiseptic. It degrades to ethylmercury and thiosalicylate.. thimerosal : An alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent.	2.31	1	0	alkylmercury compound	antifungal drug; antiseptic drug; disinfectant; drug allergen
pevonedistat pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme). pevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.	2.6	1	0	cyclopentanols; indanes; pyrrolopyrimidine; secondary amino compound; sulfamidate	antineoplastic agent; apoptosis inducer
uk 453,061 UK 453,061: a reverse transcriptase inhibitor/anti-HIV agent; structure in first source	2.6	1	0	aromatic ether
rep 3123 REP 3123: structure in first source	3.15	1	0
N-(2-aminophenyl)-2-pyrazinecarboxamide [no description available]	2.6	1	0	aromatic amide
tegobuvir tegobuvir: a non-structural protein 5B polymerase inhibitor	2.6	1	0
pf-429242 PF-429242: a subtilisin kexin isozyme-1/site-1 protease inhibitor	2.6	1	0
ro13-9904 Ceftriaxone: A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.. ceftriaxone : A third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.	2.01	1	0
quinupristin-dalfopristin quinupristin-dalfopristin: RP 59500 is a combination of RP 57669 & RP 54476, which are water soluble derivatives of pristinamycin IA & pristinamycin IIB, respectively	4.71	5	0	organic molecular entity
olaparib [no description available]	2.6	1	0	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cx 4945 [no description available]	2.6	1	0
pci 34051 PCI 34051: an HDAC8 inhibitor	2.6	1	0	indolecarboxamide
lomibuvir lomibuvir: an antiviral agent with polymerase NS5 inhibitory activity	2.6	1	0	thiophenecarboxylic acid
delanzomib [no description available]	2.6	1	0	C-terminal boronic acid peptide; phenylpyridine; secondary alcohol; threonine derivative	antineoplastic agent; apoptosis inducer; proteasome inhibitor
pitavastatin(1-) pitavastatin(1-) : A hydroxy monocarboxylic acid anion that is the conjugate base of pitavastatin, obtained by deprotonation of the carboxy group.	2.6	1	0	hydroxy monocarboxylic acid anion
GRL-0617 GRL-0617 : A benzamide resulting from the formal condensation of the carboxy group of 5-amino-2-methylbenzoic acid with the amino group of (1R)-1-(naphthalen-1-yl)ethan-1-amine. It is a potent noncovalent inhibitor (IC50 = 600 nM) of severe acute respiratory syndrome-coronavirus papain-like protease (SARS-CoV PLpro).	2.6	1	0	benzamides; naphthalenes; secondary carboxamide; substituted aniline	anticoronaviral agent; protease inhibitor
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester CAY10603: a HDAC6 inhibitor	2.6	1	0	carbamate ester
niraparib niraparib: structure in first source. niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.	2.6	1	0	2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent
jzl 184 JZL 184: inhibits monoacylglycerol lipase; structure in first source	2.6	1	0	benzodioxoles
gsk 650394 [no description available]	2.6	1	0	phenylpyridine
oprozomib ONX 0912: antineoplastic; an orally active proteasome inhibitor; structure in first source	2.6	1	0
az 960 [no description available]	2.6	1	0
(5-Chloropyridin-3-yl) 1H-indole-4-carboxylate [no description available]	2.31	1	0	indolyl carboxylic acid	anticoronaviral agent
golgicide a golgicide A: inhibits the cis-golgi ArfGEF GBF1; structure in first source. golgicide A : A diastereoisomeric mixture comprising racemic cis- and racemic trans-goglioside A in a 10:1 ratio. It is a potent and rapidly reversible GBF1 (Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1) inhibitor. The (3aS,4R,9bR) isomer is the most active (see Bioorg. Med. Chem. Lett., 2012, 22, 5177-5181).	2.6	1	0	diastereoisomeric mixture	cis-Golgi ArfGEF GBF inhibitor
cobicistat [no description available]	2.6	1	0	1,3-thiazoles; carbamate ester; monocarboxylic acid amide; morpholines; ureas	P450 inhibitor
bms-790052 daclatasvir: an HCV NS5A inhibitor. daclatasvir : A member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C.	2.6	1	0	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor
ixazomib ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.	2.6	1	0	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor
ucph 101 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile: structure in first source	2.6	1	0
cem 101 solithromycin: an antibacterial fluoroketolide; structure in first source	3.19	1	0
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine [no description available]	2.6	1	0	aryl sulfide; thienopyrimidine
baricitinib [no description available]	2.6	1	0	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
KOM70144 KOM70144 : A benzamide that is GRL-0617 in which one of the hydrogen's of the primary amino group is replaced by an acetyl group. It an inhibitor of SARS-CoV and SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 2.6 muM and 5.0 muM, respectively. It also inhibits SARS-CoV and SARS-CoV-2 infection of Vero E6 cells in vitro (EC50 values are 13.1 and 21 muM, respectively).	2.6	1	0	acetamides; benzamides; naphthalenes; secondary carboxamide	anticoronaviral agent; protease inhibitor
e-52862 [no description available]	2.6	1	0
ly2811376 [no description available]	2.6	1	0
anagliptin anagliptin: anagliptin hydrochloride salt is the active compound	2.6	1	0	amino acid amide
gardiquimod [no description available]	2.6	1	0
grazoprevir grazoprevir: has antiviral activity; component of Zepatier. grazoprevir : An azamacrocyclic compound that is a hepatitis C protease inhibitor used in combination with elbasvir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.	2.6	1	0	aromatic ether; azamacrocycle; carbamate ester; cyclopropanes; lactam; N-sulfonylcarboxamide; quinoxaline derivative	antiviral drug; hepatitis C protease inhibitor; hepatoprotective agent
abt-450 paritaprevir: inhibits HCV NS3 protease. paritaprevir : An azamacrocycle which is used which is in combination with dasabuvir sodium hydrate, ombitasvir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.6	1	0
letermovir letermovir: has antiviral activity; structure in first source	2.6	1	0
Benzyl N-[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(1,3-thiazol-2-yl)propan-2-yl]amino]pentan-2-yl]amino]-1-oxobutan-2-yl]carbamate [no description available]	2.31	1	0	dipeptide	anticoronaviral agent
colistin Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.	2.21	1	0
sofosbuvir Sofosbuvir: A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.. sofosbuvir : A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.	2.6	1	0	isopropyl ester; L-alanyl ester; nucleotide conjugate; organofluorine compound; phosphoramidate ester	antiviral drug; hepatitis C protease inhibitor; prodrug
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine sapanisertib: an mTOR inhibitor	2.6	1	0	benzoxazole
blz 945 [no description available]	2.6	1	0
azd3839 AZD3839: a BACE1 inhibitor; structure in first source	2.6	1	0
pf 3084014 nirogacestat: an antineoplastic agent. nirogacestat : A member of the class of imidazoles that is 1H-imidazole substituted by a 1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl group at position 1 and a {N-[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-L-norvalyl}amino group at position 4. It is a gamma-secretase inhibitor whose hydrobromide salt is indicated for adult patients with progressing desmoid tumours who require systemic treatment.	2.6	1	0
unc 0638 UNC 0638: inhibits lysine methyltransferases G9a and GLP; structure in first source	2.6	1	0	quinazolines
gs-9620 [no description available]	2.6	1	0
amg-837 AMG-837: GPR40 agonist	2.31	1	0
n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide: structure in first source	2.6	1	0
bms 708163 BMS 708163: structure in first source	2.6	1	0	oxadiazole; ring assembly
N-[(1R)-2-(tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide [no description available]	2.31	1	0	aromatic amide; furans
jq1 compound [no description available]	2.6	1	0	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone: a USP7 inhibitor; structure in first source	2.6	1	0
gsk525762a molibresib: mimicks acetylated histones; structure in first source	2.6	1	0	benzodiazepine
ML240 ML240 : A member of the class of quinazolines that is quinazoline which is substituted at positions 2, 5 and 8 by 2-amino-1H-benzimidazol-1-yl, benzylnitrilo and methoxy groups, respectively. It is a ATP-competetive inhibitor of AAA ATPase p97, also known as valosin-containing protein (VCP).	2.6	1	0	aromatic amine; aromatic ether; benzimidazoles; primary amino compound; quinazolines; secondary amino compound	antineoplastic agent
birinapant birinapant: a Smac mimetic with antineoplastic activity	2.6	1	0	dipeptide
ly2886721 [no description available]	2.6	1	0
nms-p118 NMS-P118: a PARP-1 inhibitor; structure in first source	2.6	1	0
tubastatin a [no description available]	2.6	1	0	hydroxamic acid; pyridoindole; tertiary amino compound	EC 3.5.1.98 (histone deacetylase) inhibitor
pracinostat pracinostat : A hydroxamic acid that is N-hydroxyacrylamide which is substituted at position 3 by a 2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl group (the E isomer). An orally available pan-histone deacetylase inhibitor with demonstrated activity in the treatment of advanced solid tumours.	2.6	1	0	benzimidazole; hydroxamic acid; olefinic compound; tertiary amino compound	antimalarial; antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
spautin-1 [no description available]	2.6	1	0
ldn 57444 LDN 57444: inhibitor of ubiquitin C-terminal hydrolase-L1; structure in first source	2.6	1	0
gsk1210151a GSK1210151A: inhibitor of the BET family of proteins; structure in first source	2.6	1	0	imidazoquinoline
i-bet726 [no description available]	2.6	1	0
acy-1215 ricolinostat: an HDAC6 inhibitor; structure in first source	2.6	1	0	pyrimidinecarboxylic acid
cudc-907 [no description available]	2.6	1	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	5.33	5	0
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	2.6	1	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
tipranavir tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.	2.6	1	0	sulfonamide	antiviral drug; HIV protease inhibitor
tasquinimod tasquinimod: a lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer; structure in first source	2.6	1	0
tigecycline [no description available]	10.49	6	0
gsk1265744 [no description available]	2.6	1	0	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor
abt-267 ombitasvir: inhibits HCV NS5A protein, component of Viekirax. ombitasvir : A dipeptide derivative which is used which is in combination with dasabuvir sodium hydrate, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.6	1	0	aromatic amide; carbamate ester; dipeptide; pyrrolidines	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor
abt-333 dasabuvir: an antiviral agent. dasabuvir : A member of the class of pyrimidone, which is (as the monohydrate of its sodium salt) in combination with ombitasvir, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	2.6	1	0	aromatic ether; naphthalenes; pyrimidone; sulfonamide	antiviral drug; nonnucleoside hepatitis C virus polymerase inhibitor
rgfp966 [no description available]	2.6	1	0
rg2833 RG2833: a histone deacetylase inhibitor; structure in first source	2.6	1	0
pi-1840 PI-1840: has both antineoplastic and proteasome inhibitory activities; structure in first source	2.6	1	0
acy-738 [no description available]	2.6	1	0
pelabresib CPI-0610: a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first source	2.6	1	0	monochlorobenzenes; organic heterotricyclic compound; primary carboxamide	antineoplastic agent; bromodomain-containing protein 4 inhibitor
gs-5806 presatovir: a respiratory syncytial virus entry inhibitor	2.6	1	0
doravirine [no description available]	2.6	1	0
gn6958 GN6958: inhibits SUMO-sentrin specific protease 1 (SENP1); structure in first source	2.6	1	0
vx-787 pimodivir: non‐nucleotide inhibitor of the polymerase basic protein 2 (PB2) subunit of the influenza A that is active against H1N1, H7N9 and H5N1, as well as influenza A strains with reduced susceptibility to NAIs	2.6	1	0
ledipasvir ledipasvir : A benzimidazole derivative that is used in combination with sofosbuvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.	2.6	1	0	azaspiro compound; benzimidazole; bridged compound; carbamate ester; carboxamide; fluorenes; imidazoles; L-valine derivative; N-acylpyrrolidine; organofluorine compound	antiviral drug; hepatitis C protease inhibitor
gs-5816 velpatasvir: an NS5A inhibitor used for treating hepatitis C infections. velpatasvir : A complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes.	2.6	1	0	carbamate ester; ether; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heteropentacyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor
g007-lk G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source	2.6	1	0
4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide 4-((1-butyl-3-phenylureido)methyl)-N-hydroxybenzamide: inhibits HDAC6; structure in first source	2.6	1	0
selinexor selinexor: inhibits karyopherin XPO1	2.6	1	0
verdinexor verdinexor: a selective inhibitor of nuclear export	2.6	1	0
cb-839 [no description available]	2.6	1	0
mk-8742 elbasvir: inhibits NS5A protein of hepatitis C virus. elbasvir : A complex organic heterotetracyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with grazoprevir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.	2.6	1	0	carbamate ester; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heterotetracyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor; hepatoprotective agent
atglistatin atglistatin: inhibits adipose triglyceride lipase; structure in first source. atglistatin : A biphenyl that is 1,1'-biphenyl substituted by (dimethylcarbamoyl)amino and dimethylamino groups at positions 3 and 4', respectively. It is a potent inhibitor of adipose triglyceride lipase activity (IC50 = 700nM).	2.6	1	0
xen445 [no description available]	2.6	1	0
santacruzamate a santacruzamate A: HDAC2 inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.; structure in first source	2.6	1	0	organonitrogen compound; organooxygen compound
ldc4297 LDC4297: a CDK7 inhibitor with antineoplastic activity; structure in first source. LDC4297 : A pyrazolotriazine that is pyrazolo[1,5-a][1,3,5]triazine substituted by a piperidin-3-yloxy group, [2-(1H-pyrazol-1-yl)benzyl]nitrilo group and an isopropyl group at positions 2, 4 and 8 respectively. It is a potent and selective CDK7 inhibitor and exhibits antiviral activity.	2.6	1	0	aromatic ether; piperidines; pyrazoles; pyrazolotriazine; secondary amino compound	antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
enasidenib [no description available]	2.6	1	0	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
bictegravir bictegravir: HIV Integrase Inhibitors. bictegravir : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxylic acid with the amino group of 2,4,6-trifluorobenzylamine. It is a second-generation integrase strand transfer inhibitor (INSTI) and used (as its sodium salt) for the treatment of HIV-1.	2.31	1	0	monocarboxylic acid amide; organic heterotetracyclic compound; secondary carboxamide; trifluorobenzene	HIV-1 integrase inhibitor
chloroeremomycin chloroeremomycin: structure given in first source. chloroeremomycin : A complex glycopeptide antibiotic that is isolated from Amycolatopsis orientalis.. chloroeremomycin(2+) : An organic cation obtained by deprotonation of the carboxy group and protonation of the three amino functions of chloroeremomycin; major species at pH 7.3.	3.87	3	0	organic cation
daptomycin [no description available]	6.21	17	0
chloroorienticin a chloroorienticin A: structure given in first source; isolated from Amycolatopsis orientalis	1.99	1	0
s 8932 [no description available]	2.6	1	0	aromatic amine; C-nucleoside; carboxylic ester; nitrile; phosphoramidate ester; pyrrolotriazine	anticoronaviral agent; antiviral drug; prodrug
entecavir entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.	2.6	1	0	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2.6	1	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
nu 1025 NU 1064: structure in first source	2.6	1	0	phenols; quinazolines	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	8.65	9	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	2.6	1	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	2.6	1	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
valacyclovir Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.	2.6	1	0	L-valyl ester	antiviral drug
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.31	1	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	2.6	1	0	2-aminopurines; propane-1,3-diols	antiviral drug
4-hydroxyquinazoline 4-oxo-3,4-dihydroquinazoline: structure in first source	2.6	1	0	quinazolines
tegaserod tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source	2.6	1	0	carboxamidine; guanidines; hydrazines; indoles	gastrointestinal drug; serotonergic agonist
norclozapine norclozapine: structure given in first source. N-desmethylclozapine : A dibenzodoazepine substituted with chloro and piperazino groups which is a major metabolite of clozapine; a potent and selective 5-HT2C serotonin receptor antagonist.	2.6	1	0	dibenzodiazepine; organochlorine compound; piperazines	delta-opioid receptor agonist; metabolite; serotonergic antagonist
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	2.6	1	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	2.6	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
ceftobiprole ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).	5.49	6	0	cephalosporin; thiadiazoles	antimicrobial agent
azilsartan azilsartan: an angiotensin type 1 receptor blocker; receptor blocker. azilsartan : A benzimidazolecarboxylic acid that is benzimidazole-7-carboxylic acid substituted at position 2 by a methoxy group and at position 1 by a 2'-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl group. Used (as the prodrug, azilsartan medoxomil) for treatment of hypertension.	2.6	1	0	1,2,4-oxadiazole; aromatic ether; benzimidazolecarboxylic acid	angiotensin receptor antagonist; antihypertensive agent
hesperadin [no description available]	2.6	1	0
6-bromoindirubin-3'-acetoxime 6-bromoindirubin-3'-acetoxime: a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, protects cells from varicella infection	2.6	1	0
amg531 [no description available]	2.31	1	0
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide [no description available]	2.6	1	0	catechols; hydrazide; hydrazone; naphthols	EC 3.6.5.5 (dynamin GTPase) inhibitor
XL413 XL413 : A benzofuropyrimidine that is 3,4-dihydro[1]benzofuro[3,2-d]pyrimidine substituted by (2S)-pyrrolidin-2-yl, oxo and chloro groups at positions 2, 4, and 8, respectively. It is a potent ATP competitive inhibitor of Cdc7 kinase (IC50 = 3.4 nM) and exhibits anticancer properties.	2.6	1	0	benzofuropyrimidine; organochlorine compound; pyrrolidines	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
me0328 ME0328: inhibits ARTD3; structure in first source	2.6	1	0
nvp-tnks656 [no description available]	2.6	1	0
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-cyclohexyl-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-alaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.53 muM).	2.31	1	0	aldehyde; indolecarboxamide; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide 3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-fluoro-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.72 muM).	2.31	1	0	aldehyde; indolecarboxamide; monofluorobenzenes; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor

Condition	Indicated	Relationship Strength	Studies	Trials
Bacterial Disease [description not available]	0	5.4	7	0
Bacterial Infections Infections by bacteria, general or unspecified.	1	7.4	7	0
Bacillus anthracis Infection [description not available]	0	2.04	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.92	12	0
Anthrax An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.	0	7.04	1	0
Cystic Fibrosis of Pancreas [description not available]	0	2.05	1	0
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	0	2.05	1	0
Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.	0	4.61	5	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Bacterial Skin Diseases [description not available]	0	14.11	39	8
Skin Diseases, Bacterial Skin diseases caused by bacteria.	0	14.11	39	8
Infections, Soft Tissue [description not available]	0	8.53	11	1
Soft Tissue Infections Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688)	0	13.53	11	1
Benign Neoplasms [description not available]	0	2.69	2	0
Infections, Staphylococcal [description not available]	0	9.28	33	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.69	2	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	0	9.28	33	2
Phlegmon [description not available]	0	4.27	5	0
Cellulitis An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.	0	9.27	5	0
Bacterial Infections, Gram-Positive [description not available]	0	11.72	54	2
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	0	11.72	54	2
Catheter-Associated Infections [description not available]	0	3.5	2	0
Bone Diseases, Infectious Bone diseases caused by pathogenic microorganisms.	0	3.17	1	0
Cardiovascular Infections Pathological conditions of the CARDIOVASCULAR SYSTEM caused by infections.	0	3.17	1	0
Bacterial Endocarditides [description not available]	0	3.85	4	0
Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.	0	3.85	4	0
Chemical Dependence [description not available]	0	2.25	1	0
Substance-Related Disorders Disorders related to substance use or abuse.	0	2.25	1	0
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	0	2.31	1	0
Atypical Mycobacterial Infection, Disseminated [description not available]	0	2.31	1	0
Segond Fracture [description not available]	0	2.15	1	0
Infection, Postoperative Wound [description not available]	0	2.15	1	0
Tibial Fractures Fractures of the TIBIA.	0	2.15	1	0
Infectious Skin Diseases [description not available]	0	6.51	5	1
Injuries Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.	0	3.09	1	0
Skin Diseases, Infectious Skin diseases caused by bacteria, fungi, parasites, or viruses.	0	6.51	5	1
Wounds and Injuries Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.	0	3.09	1	0
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	0	5.76	7	1
Health Care Associated Infection [description not available]	0	5.17	10	0
Cross Infection Any infection which a patient contracts in a health-care institution.	0	5.17	10	0
Bacterial Infections, Gram-Negative [description not available]	0	3	1	0
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	0	3	1	0
Acute Disease Disease having a short and relatively severe course.	0	7.51	7	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	0	4.4	1	1
Group A Strep Infection [description not available]	0	2.77	3	0
Streptococcal Infections Infections with bacteria of the genus STREPTOCOCCUS.	0	2.77	3	0
Infection, Wound [description not available]	0	3.03	1	0
Adverse Drug Event [description not available]	0	3.03	1	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	3.03	1	0
Hospital-Acquired Condition [description not available]	0	3.04	1	0
Infections, Staphylococcal Skin [description not available]	0	5.52	5	1
Staphylococcal Skin Infections Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.	0	5.52	5	1
Abscess, Abdominal [description not available]	0	3.04	1	0
Abdominal Abscess An abscess located in the abdominal cavity, i.e., the cavity between the diaphragm above and the pelvis below. (From Dorland, 27th ed)	0	3.04	1	0
Community Acquired Infection [description not available]	0	2.96	4	0
Infections, Prosthesis-Related [description not available]	0	2.45	2	0
Antibiotic-Associated Colitis [description not available]	0	3.65	3	0
Enterocolitis, Pseudomembranous An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.	0	3.65	3	0
Bacterial Pneumonia [description not available]	0	2.96	1	0
Infections, Pseudomonas [description not available]	0	2.96	1	0
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	0	2.96	1	0
Pneumonia, Bacterial Inflammation of the lung parenchyma that is caused by bacterial infections.	0	2.96	1	0
Skin Diseases, Viral Skin diseases caused by viruses.	0	2.05	1	0
Clostridioides difficile Infection [description not available]	0	2.48	2	0
Clostridium Infections Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species.	0	2.48	2	0
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	2.01	1	0
Experimental Pneumococcal Meningitis [description not available]	0	2.41	2	0
Meningitis, Pneumococcal An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111)	0	2.41	2	0
Diffuse Large B-Cell Lymphoma [description not available]	0	2.01	1	0
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	0	2.01	1	0
Diabetic Feet [description not available]	0	2.02	1	0
Leg Ulcer Ulceration of the skin and underlying structures of the lower extremity. About 90% of the cases are due to venous insufficiency (VARICOSE ULCER), 5% to arterial disease, and the remaining 5% to other causes.	0	2.02	1	0
Foot Ulcer Lesion on the surface of the skin of the foot, usually accompanied by inflammation. The lesion may become infected or necrotic and is frequently associated with diabetes or leprosy.	0	2.02	1	0
Diabetic Foot Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.	0	2.02	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.02	1	0
Bleb [description not available]	0	2.02	1	0
Lysosomal Enzyme Disorders [description not available]	0	2.02	1	0
Critical Illness A disease or state in which death is possible or imminent.	0	2.94	1	0

oritavancin

Description

Cross-References

Synonyms (41)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (3)

Protein Targets (2)

Inhibition Measurements

Biological Processes (1)

Molecular Functions (12)

Ceullar Components (1)

Bioassays (283)

Research

Studies (240)

Market Indicators

Research Demand Index: 53.19

Study Types

Clinical Trials (18)

Trial Overview

Trial Outcomes

Cessation Of Spread Or Reduction In Size Of Baseline Lesion, Absence Of Fever, And No Rescue Antibiotic Medication At Early Clinical Evaluation (ECE) (48 To 72 Hours)

Investigator Assessed Clinical Cure Of Treatment With Single-dose IV Oritavancin Compared With IV Vancomycin For 7 To 10 Days At Post-therapy Evaluation (Key Secondary Endpoint)

Number Of Participants With A Lesion Size Reduction ≥20% From Baseline At ECE

>= 20% Reduction in Lesion Area

Early Clinical Response

Investigator Assessed Clinical Cure at Post Therapy Evaluation (Key Secondary Endpoint)

Number of Participants With a Clinical Response of Cure

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Number of Subjects With at Least One Treatment Emergent Adverse Event (TEAE)

Relative Exposure of AUC of the New Formulation to the Approved Formulation

Relative Exposure of AUC of the New Formulation to the Approved Formulation

Related Drugs (698)

Related Conditions (79)